Document:

exv10w1

 

Exhibit 10.1

Subject: Amendment No. 92 to Standard Aero Subcontract

     Reference: (1) KAC Subcontract No. LMKAC-98-0001

This amendment incorporates changes to the reference subcontract, as detailed below. These
changes supersede the existing contract terms and conditions and are effective upon execution by
both parties.

     BASIC TERMS AND CONDITIONS:

Section 2.1, Services to be Provided, is amended as follows:

A. EXCLUSIVE PROVIDER

Standard Aero shall be the sole and exclusive provider of all labor and material for the T56 PBA
work through February 2014, or the duration of the PBA program, whichever is longer. This
relationship shall not be modified except as provided herein.

B. PROGRAM SUMMARY

(STET)

 

Section 4.2, Option Periods, is replaced and amended to read as follows in its entirety:

     Subsequent to the initial ordering period, KAC agrees to exercise options for annual
increments in accordance with the Award Term Decisions and the Award Term Clause, H-900, of the
KAC/OC-ALC Contract, No. F34601-99-D-0002. Subsequent extensions shall be flowed down
automatically without further restrictions or conditions, and shall not be dependent upon
performance, provided that award terms are received by KAC. In the event that any previously
earned and awarded Award Term extensions or options are withdrawn by the Government, the parties
agree to adjust the length of the Subcontract accordingly.

 

Article 5, Payment, is amended to read as follows:

Payment terms shall be 30 days from receipt of a valid invoice by wire with a 1% interest
penalty per month (prorated by day) for any payment not received within 30 days. All other
payment terms are defined in Exhibit F.

 

Section 7.1 is renamed “Annual Fiscal Year Criteria for Award Term Performance Metrics,” replaced
and amended to read as follows in its entirety:

Page 1 of 12

[/ \
INDICATES THAT CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AND THE
HIGHLIGHTED INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION.]

 

1. The “End-of-Period” Evaluation for Product Quality and Schedule as determined by the USAF
for each fiscal year, commencing with FY07, will be flowed down to the KAC-Standard Aero
subcontract performance metrics.

2. Standard Aero Performance shall be evaluated annually. In that actual damages would be difficult
or impossible to ascertain, Standard Aero shall pay KAC Liquidated Damages (“LD” or “LDs”) for
unsatisfactory performance beginning in FY 2007. Schedule and Quality evaluations will be
determined per annual USAF ATRB determinations and applied to LDs as a percentage of the applicable
Award Conversion Scale for each sub-category. Management Responsiveness will be determined by and
reflected in an annual written review of Standard Aero’s performance from KAC to coincide with the
issuance of USAF ATRB results and applied on a percentage basis of unsatisfactory events/total
events. KAC shall also provide a detailed written report to SASA on its performance reflecting the
CPAR rating for the T56 Engine Work on the PBA Contract by December 31 of each year. Standard Aero
LDs will be determined in accordance with the following schedule.

     Table 1 — Annual Standard Aero Performance Evaluation 

	 	 	 	 	 	 	 
	EVALUATION AREA	 	EXCELLENT &	 	 
	(and Sub-Categories)	 	SATISFACTORY	 	UNSATISFACTORY
	 	 	 	 	Evaluation Criteria	 	 
	 	 	 	 	(Award % determination)	 	Liquidated Damages
	Schedule:
	 	 	 	Per ATRB Award	 	Calculation
	T56 EMM Schedule
	 	$0.00	 	0 (0%) to --5 (100%)	 	[/ \] x Award %
	T56 MISTR A Schedule
	 	$0.00	 	0 (0%) to --1 (100%)	 	[/ \] x Award %
	T56 MISTR B Schedule
	 	$0.00	 	0 (0%) to --1 (100%)	 	[/ \] x Award %
	Total:	 	$0.00	 	Max Schedule LD amount @ 100% = [/ \]
	Product Quality:
	 	 	 	Per ATRB Award	 	 
	T56 EMM Quality
	 	$0.00	 	0 (0%) to --5 (100%)	 	[/ \] x Award %
	T56 Component Quality
	 	$0.00	 	0 (0%) to --2 (100%)	 	[/ \] x Award %
	Total:	 	$0.00	 	Max Product Quality LD amount @ 100% = [/ \]
	Mgmt Responsiveness:
	 	 	 	Per KAC Evaluation	 	 
	Delivery of RFPs
	 	$0.00	 	% of (Unsat Events	 	[/ \] x Eval %
	 
	 	 	 	/Total Events)	 	 
	Delivery of TRD reports
	 	$0.00	 	% of (Unsat Events	 	[/ \] x Eval %
	 
	 	 	 	/Total Events)	 	 
	Shipment of Winnipeg
	 	$0.00	 	% of (Unsat Events	 	[/ \] x Eval %
	assets
	 	 	 	/Total Events)	 	 
	Total:	 	$0.00	 	Max Mgmt Resp. LD amount @ 100% = [/ \]
	MAX. TOTAL:	 	Maximum Total LDs @ 100% = $2,000,000.00

Page 2 of 12

[/ \
INDICATES THAT CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AND THE
HIGHLIGHTED INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION.]

 

     Table 2 — Evaluation Area Criteria 

	 	 	 
	SCHEDULE

	 	[/ \ / \]

	 

	 	 

	 

	 	 

	 

	 	 

	 
	PRODUCT QUALITY

	 	[/ \ / \]

	 

	 	 
	 

	 	 
	 
	MANAGEMENT RESPONSIVENESS

	 	[/ \ / \]

	• Evaluation of Standard Aero
performance in each sub-category by
KAC for annual FY events to coincide
with timing of USAF ATRB reviews.

	 	 
	 

	 	 
	• Based on working days; one day = 24 hours.
• Categorization of RFPs as
Simple or Complex will be mutually
agreed by KAC and Standard Aero on a
case by case basis.

	 	 [/ \ / \]

	 

	 	 
	 

	 	 
	 

	 	 
	 

	 	 
	 

	 	 
	 

	 	 
	 
	 	 
	 

	 	 
	 

	 	[/ \ / \]

	 

	 	 
	 

	 	 
	 

	 	 

3. If any LDs are assessed, payment will be due from Standard Aero to KAC within 45 days of
Standard Aero’s notification by KAC of the USAF’s ATRB official rating to KAC.

4. LDs shall take effect commencing in FY07 for the duration of the PBA program.

5. In the event that an “Unsatisfactory” rating is awarded in two successive years in a specific
Evaluation Area sub-category (e.g., T56 EMM), the LD amount payable in that sub-category per
Table 1, Annual Standard Aero Performance Evaluation, will be doubled in the second
(2nd) year and will remain at the doubled level for successive years of unsat in
that Evaluation Area sub-category; but under no circumstances, will the annual LD payable ever
exceed this double amount.

6. Standard Aero shall have the right to dispute any imposition by KAC of LDs for Management
Responsiveness pursuant to Article 16 hereof under an arbitrary and capricious or abuse of
discretion standard of review. Standard Aero shall not have a right to dispute evaluations of
Schedule or Quality which shall be a pass through of such evaluations received by KAC under
the PBA Contract except Standard Aero may dispute such evaluations through KAC to the extent
KAC agrees to dispute such evaluation(s) under the PBA Contract.

Page 3 of 12

[/ \
/ \ INDICATES THAT CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR THE DATA IN THIS COLUMN; IT HAS BEEN OMITTED AND FILED
SEPARATELY WITH
THE COMMISSION.]

 

7. Notwithstanding any provision herein to the contrary, nothing shall impose upon Standard Aero
any LD for which Rolls-Royce is the sole or primary contributing cause.

8. KAC and Standard Aero agree to work together to ensure that the ATRB evaluation criteria
applied to the quality metric will continue to be based only on Standard Aero’s workmanship.
In no event shall Standard Aero be subject to financial penalties resulting from any defects
in Rolls-Royce supplied material. The warranty obligations of Standard Aero with respect to
labor and secondary damages shall remain as it currently is.

 

     Article 13, Delays, Default, Termination, is replaced and amended to read as follows in its
entirety

     The Parties’ rights and remedies regarding delays, default, and termination under this
Subcontract, shall be in accordance with FAR Clause 52.212-4, except that KAC may only terminate
the Subcontract for convenience if its Contract with OC-ALC, No. F34601-99-D-0002, is terminated
for convenience by the US Government, and then only to the same extent.

 

     Section 19.4.2, Government’s Rights in Data, is replaced and amended to read as follows in its
entirety:

     The Parties agree that the Government’s rights, if any, in data shall be governed by DFARS
Clause 252.227-7015, Technical Data—Commercial Items, which is specifically incorporated herein.
KAC will not impede efforts by Standard Aero to obtain the Government’s agreement to treat data
that originated solely with Standard Aero and that Standard Aero caused to be delivered to the
Government prior to Subcontract Amendment No. 92 as subject to DFARS 252.227-7015(b)(2), and to
correct any markings or notices on the documents accordingly, if necessary, at Standard Aero’s
expense. KAC will forward to the government any such request by Standard Aero. Standard Aero
shall hold KAC harmless for any and all damages, costs, causes of action, withholdings or expenses
arising out of or relating to (i) any treatment of Standard Aero data delivered to the Government
prior to Subcontract Amendment No. 92 as other than DFARS 252.277-7015(b)(2) data and (ii) Standard
Aero’s efforts to obtain treatment for such data under DFARS 252.227-7015(b)(2).

 

Exhibit L, incorporated into the Subcontract in Section 19.4.3, Proprietary Information Agreement,
is amended to add the following new paragraphs 5, 6 and 7 and renumbering the remaining paragraphs:

5. Except as specifically agreed to herein or subsequently in writing, KAC agrees to take the same
reasonable measures set forth above to prevent disclosure of Standard Aero’s Proprietary
Information to Rolls-Royce or its officers, directors, consultants or employees. KAC further
agrees that, except as agreed to herein or subsequently in writing, Rolls-Royce’s officers,
directors, consultants or employees shall not be permitted access to any work areas regularly used
by Standard Aero.

Page 4 of 12

 

6. Notwithstanding paragraph 5, if KAC in good faith determines that performance of the Prime
Contract requires limited disclosure of Standard Aero Proprietary Information to one or more of
Rolls-Royce’s officers, consultants or employees, KAC shall seek Standard Aero’s written permission
to permit disclosure to such specified individual. Standard Aero shall not unreasonably withhold
permission provided that (i) the designated individual is not involved in competitive
decisionmaking as defined in U.S. Steel Corp. v. United States, 730 F.2d 1465 (Fed. Cir. 1984);
(ii) the designated individual executes an Undertaking in the form set forth below; (iii) the total
number of such designated individuals at any time does not exceed six; and (iv) the request for
permission describes the Proprietary Information to which the individual will have access.

UNDERTAKING

I,                                                             , hereby certify as follows:

1. I am affiliated with the Rolls Royce Corporation (“RRC”) as follows:

 

 

 

2. I have read Paragraph 19.4.3 of the Contract between Kelly Aviation Center, LLC and Standard
Aero (San Antonio), Inc. (“Standard Aero”), and I agree to be bound by the provisions of that
paragraph (the “PIA”). I further agree that (i) I will only review Proprietary Information
produced by Standard Aero at KAC’s offices, (ii) I will not take copies of such information to
RRC’s offices or elsewhere, (iii) I will not disclose any such Proprietary Information to any other
RRC officer, director, employee or consultant, or any third party, and (iv) I will take all
reasonable measures to prevent such disclosure of Standard Aero’s Proprietary Information.

3. I am not involved in competitive decisionmaking as discussed in U.S. Steel Corp. v. United
States, 730 F.2d 1465 (Fed. Cir. 1984), for or on behalf of RRC or any other party or entity
that might gain a competitive advantage from access to any Proprietary Information disclosed
pursuant to the Contract. This means that I do not, for example, provide advice concerning or
participate in decisions about marketing or advertising strategies, product research and
development, product design or competitive structuring and composition of bids, offers, or
proposals with respect to which the use of such Proprietary Information could provide a competitive
advantage.

CERTIFICATION

By my signature, I certify that, to the best of my knowledge, the representations set forth above
(including any attached statements) are true and correct.

	 	 	 
	 
	 	 
	 

	 	 
	Signature

	 	Date Executed
	 
	 	 
	 
	 	 
	 	 	 
	 
	 	 
	Printed Name and Title
	 	 

 

Page 5 of 12

 

7. The provisions of sections 5 and 6 shall, at Standard Aero’s sole discretion, also apply to any
additional general or limited partners of KAC.

Article 23, Subcontract Administration Provisions, is amended to add the following:

23.4
PROTOCOL FOR STANDARD AERO DISCUSSIONS WITH KAC’S PBA
CUSTOMERS

1. Standard Aero shall not initiate any discussions related to PBA Work (technical or other)
directly with KAC’s PBA customers (USAF, NAVICP, USCG or their field and using command customers)
without KAC knowledge or involvement that is outside of the specific authorizations below. Nothing
herein shall affect Standard Aero’s rights to discuss with any person or entity non-PBA work.
[/ \]

2. Under the circumstances and allowances below (and only under these circumstances) Standard Aero
will continue to work directly with a PBA customer on/with:

a) Quarantined Parts — Direct discussions are permissible.

b) Quarantine Report — Direct discussions are permissible but ensure KAC’s Subcontractor Mgmt and
Program Office is copied.

c) AFTO 202s — These can continue to go directly to the USAF CEA with a copy KAC’s Subcontractor
Mgmt, Chief Engineer, KAC Technical Library and Program Office. The library will send a scanned
copy of all 202s to the KAC contact list below. Note: Any 202s or REIs that are requesting an MRB
disposition, for a condition that was the result of a Standard Aero workmanship error, or
discrepant PBA quality, should be brought to the attention of Standard Aero quality and then
coordinated with KAC Chief Inspector’s office before it is exposed to the PBA customers.

d) DCMA — In case DCMA directly calls Standard Aero on PBA technical issues, Standard Aero shall
treat it the same as above for the technical discussions (above), answer the question, and notify
the KAC Chief Inspector. If the call is to discuss a particular DR, DRs in general or quality
issues, Standard Aero shall either get the KAC Chief Inspector on the line or ask that they go
through KAC Quality. Standard Aero will not let a technical discussion turn into a quality
discussion. If DCMA comes over with questions or issues concerning PBA contract production or
quality, they will be redirected to KAC.

e) CEMS — Issues raised from field bases and OC-ALC program office personnel can be handled
directly. This includes: release of assets in CEMS, general maintenance of CEMS data, day-to-day
upkeep of CEMs records. If a conversation or issue turns into a systemic issue, an issue that will
impact Standard Aero’s ability to deliver, problems with the quality of our data in CEMS, adverse
trends or anything that sounds like an issue with PBA quality — Standard Aero shall stop and refer
the call to KAC quality and work the call/issue with KAC.

Page 6 of 12

[/ \ INDICATES THAT CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED AND THE HIGHLIGHTED INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH
THE COMMISSION.]

 

f) Process Qualifications/Repair Development — Standard Aero can continue to work directly with
the PBA OC-ALC customer or their representative on these issues, provided that, KAC’s chief
engineer is consulted prior to any discussions. The Standard Aero Engineering Director will provide
to the KAC’s Engineering, Subcontract, Quality Assurance and Program Office a quarterly status of
the ongoing and outstanding process qualification packages.

g) Field Service Visits — These will be pre-coordinated with KAC Quality and the respective PBA
customer’s program offices before deploying resources to fix a PBA unit in the field. Standard
Aero quality shall get KAC Quality involved as soon as the call/notification comes in.

h) Technical Conferences — PBA Users Conf (USAF or USN), CIP, MPWG — As soon as Standard Aero
knows about these conferences, they will send an email to the KAC contact list below. Include the
dates, location, agenda and arrangements. KAC will participate with Standard Aero in these events.
Standard Aero shall not attend or discuss these events (excluding CIP) without KAC knowing in
advance what is expected to be briefed/discussed.

i) Non-technical Conferences or Meetings with PBA customers (Co- Forecasting, Award term review,
PMR and any performance evaluations directly related to Standard Aero’s PBA work) — KAC will
participate at all times unless it chooses not to do so.

j) PBA Customer Service Visits to Bases — These will be coordinated with KAC before hand.
Coordinate all potential visits with the KAC Program office.

k) PBA Customer requests (Program Office or Field Requests) for technical Info (email or phone) or
for Help/Trouble Shooting an engine problem — It is acceptable for Standard Aero to provide
non-protected/non-restricted shared technical experiences, its knowledge and any history it has on
a technical issue. Under no circumstances except as agreed herein should Standard Aero be
discussing PBA quality, contract or production issues. Ultimately, Standard Aero will let any
field users know that they need to call their respective DoD Program Offices for guidance,
coordination and authorization (i.e. OC-ALC/LPE, or the USN FST, NAVICP or the USCG C-130 Program
Office). If Standard Aero suspects that a PBA quality or contracts issue could arise from the
conversation, immediately email or call the KAC Chief Inspector/Quality office.

l) Request for info from the DML
PMS or Prog Mgmt functions —  Standard Aero shall direct them to
the KAC Contracts Mgr.

m) Expediting Parts directly with DLA — Standard Aero can go directly to DLA, but make sure that
KAC get the critical items list, and is informed of the items we are attempting to expedite
(potential work stoppage items). We must make sure that KAC is aware of any parts constraints
before their customer is aware. Err on the side of too much info in this area. Notify KAC Supply
Chain Management (attn: Joe Hernandez)

n) Expediting of GFM material — If GFM items need to be expedited due to production impacts;
Standard Aero will advise KAC Supply Chain Mgmt of such impacts, potential stoppages on the
shortage reports and comments column of production reports. Those expedite calls can be made to
insure that everything possible is done to alleviate work stoppage and sales impacts. Standard
Aero should make sure that KAC is aware of any parts constraints before their customer is aware.
Err on the side of too much info in this area.

o) Paint schemes and destination requests — Standard Aero will coordinate this info directly with
the PBA customer, but copy the KAC program office on all communications.

Page 7 of 12

 

p) DREAMS system input: Standard Aero will input the DRs on GFM material via DREAMS. A status
report from DREAMS is to be supplied to the KAC Subcontract Mgr to distribute as necessary.

3. Customer contact not covered above:

a) If a PBA customer contacts Standard Aero personnel directly regarding PBA work that is an issue
not covered by this Protocol list, Standard Aero shall call the KAC PBA program office who will in
turn notify the KAC responsible department.

b) In reference to purely technical discussions not covered above, KAC does not want to impede the
necessary technical dialogue from occurring between engineering departments, but at the same time
the discussions should be limited to technical discussions only. However, KAC should be advised of
any potential impacts or issues that affect the program. As the protocol has been from the
inception of the contract, the KAC Chief Engineer will be kept involved in all technical issues.
This can be done after the fact through phone calls and emails. If a technical discussion turns
into, or brings out, a quality issue (against the PBA contract) that has not been pre-coordinated
with KAC, stop the conversation. Notify Standard Aero quality and the Standard Aero PBA Program
office and reschedule the discussion with KAC contacts on the line.

c) All other conversations should not occur unless KAC is involved in the call or has provided
specific guidance to proceed without their involvement.

d) Below is the current contact list for key KAC personnel that Standard Aero should be
coordinating issues with:

	 	 	 
	[/ \]

KAC Chief Engineer

	 	[/ \]

	 
	 	 
	[/ \]

PBA Program Manager

	 	[/ \]

	 
	 	 
	[/ \]

Subcontracts Manager

	 	[/ \]

	 
	 	 
	[/ \]

Subcontracts Administrator

	 	[/ \]

	 
	 	 
	[/ \]

Contracts Manager

	 	[/ \]

	 
	 	 
	[/ \]

Chief Inspector

	 	[/ \]

	 
	 	 
	[/ \]

Quality Assurance Analyst

	 	[/ \]
 (Beeper [/ \]
) 

Page 8 of 12

[/ \ INDICATES THAT CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED AND THE HIGHLIGHTED INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH
THE COMMISSION.]

 

 

SP. 7.0, Standard Aero’s Personnel, is amended to add the following:

5. Each party reserves the right to advertise for open positions but agrees not to target any
particular employees of the other for hire, without written consent, during the PBA Contract and
for one year thereafter, and for the duration of any subcontract awarded for Post-PBA T56 Work
pursuant to the terms of the Teaming Agreement. Nothing herein shall prohibit either party from
hiring a former employee of the other party one year or more after the prior employment was
terminated.

 

SP 10.0 is amended to add the following:

	(j) Notwithstanding the above, Standard Aero shall provide KAC annual price reductions as
follows:

     (i) FY 2007:
$[/ \]
 commencing October 1, 2006.

     (ii) FY 2008 through
end of PBA term: [/ \]
% of the annual TAP determined from the annual BEQs
excluding “over and above” work.

(k) The initial TAP for each year shall be the prior year’s TAP before application of the prior
year’s price reductions as depicted on the following Table:

Page 9 of 12

[/ \ INDICATES THAT CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED AND THE HIGHLIGHTED INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH
THE COMMISSION.]

 

Note: All amounts are estimates for illustrative purposes. All figures in USD$000,000.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Year	 	FY07	 	FY08	 	FY09	 	FY10	 	FY11	 	FY12	 	FY13	 	FY14
	[/ \ / \]

	 	$[/ \ / \]
	$[/ \ / \]
	$[/ \ / \]
	[/ \ / \]
	[/ \ / \]
	 	[/ \ / \]
	 	[/ \ / \]
	 	[/ \ / \]

	[/ \ / \]
	 	$[/ \ / \]
	$[/ \ / \]
	$[/ \ / \]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[/ \ / \]

	 	$[/ \ / \]
	$[/ \ / \]
	$[/ \ / \]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[/ \ / \]

	 	$[/ \ / \]
	$[/ \ / \]
	$[/ \ / \]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[/ \ / \]

	 	$[/ \ / \]
	$[/ \ / \]
	$[/ \ / \]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[/ \ / \]

	 	$[/ \ / \]
	$[/ \ / \]
	$[/ \ / \]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[/ \ / \]

	 	$[/ \ / \]
	$[/ \ / \]
	$[/ \ / \]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[/ \ / \]

	 	$[/ \ / \]
	$[/ \ / \]
	$[/ \ / \]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[/ \ / \]
	 	$[/ \ / \]
	$[/ \ / \]
	$[/ \ / \]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Year	 	FY07	 	FY08	 	FY09	 	FY10	 	FY11	 	FY12	 	FY13	 	FY14
	[/ \ / \]

	 	$[/ \ / \]
	$[/ \ / \]
	$[/ \ / \]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[/ \ / \]

	 	 [/ \ / \]
	 [/ \ / \]
	 [/ \ / \]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[/ \ / \]

	 	 [/ \ / \]%
	 [/ \ / \]%
	 [/ \ / \]%
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[/ \ / \]

	 	 [/ \ / \]
	 [/ \ / \]
	 [/ \ / \]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[/ \ / \]

	 	 [/ \ / \]
	 [/ \ / \]
	 [/ \ / \]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[/ \ / \]

	 	 [/ \ / \]%
	 [/ \ / \]%
	 [/ \ / \]%
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[/ \ / \]

	 	 [/ \ / \]
	 [/ \ / \]
	 [/ \ / \]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[/ \ / \]

	 	 [/ \ / \]
	 [/ \ / \]
	 [/ \ / \]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[/ \ / \]

	 	 [/ \ / \]
	 [/ \ / \]
	 [/ \ / \]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[/ \ / \]

	 	 [/ \ / \]%
	 [/ \ / \]%
	 [/ \ / \]%
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[/ \ / \]

	 	 [/ \ / \]
	 [/ \ / \]
	 [/ \ / \]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[/ \ / \]

	 	 [/ \ / \]
	 [/ \ / \]
	 [/ \ / \]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[/ \ / \]

	 	 [/ \ / \]%
	 [/ \ / \]%
	 [/ \ / \]%
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[/ \ / \]

	 	 [/ \ / \]
	 [/ \ / \]
	 [/ \ / \]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[/ \ / \]

	 	 [/ \ / \]
	 [/ \ / \]
	 [/ \ / \]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[/ \ / \]

	 	 [/ \ / \]%
	 [/ \ / \]%
	 [/ \ / \]%
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[/ \ / \]

	 	$[/ \ / \]
	 [/ \ / \]%
	 [/ \ / \]%
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

Page 10 of 12

[/ \
/ \ INDICATES THAT CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR THE DATA IN THIS COLUMN; IT HAS BEEN OMITTED AND FILED
SEPARATELY WITH
THE COMMISSION.]

 

FY07 Opening TAP = FY06 Unit Prices X FY07 BEQs

FY08 Opening TAP = FY07 August TAP Unit Prices X FY08 BEQs

FY09 Opening TAP = FY08 August TAP Unit Prices x FY09 BEQs

Price reduction in FY07 is fixed at $[/ \].

Price reduction in all other years is fixed at [/ \]% of actual TAP.

Per Section H-901 of F34601-99-D-0002

Economic Price Adjustment

* Material Index Use: Sept of each year

** Labor Index Use: 3rd Qtr of each year

(l) In determining proposed prices, Standard Aero shall apply
[/ \]

(m) Other than as set forth in subparagraph (j), KAC is not entitled to, and shall not seek, any
further pricing reductions from Standard Aero while this Subcontract is in effect.

 

SP 12.0, Establishment of DLA as a Direct, CFM Source of Supply for Kelly Aviation Center L.P
(KAC)(Aug. 2002), incorporated into the reference subcontract agreement through Amendment 36, is
amended as follows:

(i) Paragraph (a): Change “contractor” to “Standard Aero.” Delete: “and In Accordance With (IAW)
DLA/KAC L.P. Agreement 03-0001.” At the end of the paragraph, add: Notwithstanding this
authorization, Standard Aero may order parts from other approved US Government sources of supply
at Standard Aero’s discretion.

(ii) Paragraph (f): Amend paragraph to read:

“If Standard Aero chooses to acquire items from sources other than DLA, for those items converted
to CFM under this provision, Standard Aero shall notify KAC. If Standard Aero intends the change
to be permanent, Standard Aero will recompute its Exhibit “E” and “K” unit prices to reflect the
new prices and establish a new Exhibit “E” price. In no event shall the Exhibit “E” price exceed
the latest established Exhibit “E” price. Additionally, prior to any acquisition from vendors
other than DLA as a result of this permanent change, Standard Aero agrees to purchase the Depot
share of those affected DLA assets stocked to support the PBA contract (i.e, Standard Aero may
deplete the stocked assets on hand at the time of Standard Aero’s notice to KAC, or may make a
one-time buy of those assets on hand). If Standard Aero intends the change to be temporary due to
the inability of DLA to fill immediate requirements, an adjustment will be negotiated as deemed
necessary between Standard Aero and KAC on the one hand, and OC-ALC on the other. [/ \].”

(iii) Paragraphs (g) and (h): Change “KAC” to “Standard Aero.

	 	 	 	 	 

Page 11 of 12

[/ \ INDICATES THAT CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED AND THE HIGHLIGHTED INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH
THE COMMISSION.]

 

	 	 	 	 	 
	Date: July, 11, 2006 	STANDARD AERO [SAN ANTONIO], INC.

 	 
	 	By:  	 /s/ Edward S. Richmond 
	 
	 	 	Edward S. Richmond 	 
	 	Title:  	Senior Vice President 	 
	 
	Date: July, 11, 2006 	KELLY AVIATION CENTER, LP

 	 
	 	By:  	 /s/
Marillyn Hewson 	 
	 	Name:  	Marillyn Hewson 	 
	 	Title:  	President 	 
	 

Page 12 of 12exv10w1

 

Exhibit 10.1

EXECUTION COPY

THE REGISTRANT HAS APPLIED FOR CONFIDENTIAL TREATMENT OF CERTAIN PROVISIONS OF THIS EXHIBIT WITH
THE SECURITIES AND EXCHANGE COMMISSION. THE CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE MARKED WITH
ASTERISKS (***) AND HAVE BEEN OMITTED. THE OMITTED PORTIONS OF THIS EXHIBIT WILL BE FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT.

LICENSE AND DEVELOPMENT AGREEMENT

     This agreement (“Agreement”) entered into this [   ]th day of [                    ], 2006 (the “Effective Date”) by and between NOVAVAX, INC., a Delaware corporation having an
address at 508 Lapp Road Malvern, Pennsylvania 19355 (hereinafter referred to as “NOVAVAX” or
"Party”) and ESPRIT Pharma, Inc., a Delaware corporation having an address at 2 Tower Center
Boulevard, East Brunswick, NJ 08816, (hereinafter referred to as “ESPRIT” or “Party”). Capitalized
terms used herein and not otherwise defined shall have the meanings ascribed in ARTICLE 1
(Definitions).

WITNESSETH

     WHEREAS, NOVAVAX is the owner of a Investigative Drug Application No. 63957, as well as U.S.
Patent No. 5,629,021, Canadian Patent No. 2,211,262, Mexican Patent No. 198,438 other patents and
patent applications, and know-how relating micellar nanoparticle technology.

     WHEREAS, ESPRIT wishes to acquire an exclusive license under such patents and patent
applications from NOVAVAX, and NOVAVAX is willing to grant such license to ESPRIT under the terms
and conditions of this Agreement.

     WHEREAS, concurrently with the execution and delivery of this Agreement, the parties have
entered into the Supply Agreement relating to the supply of Licensed Product and the provision of
related services by NOVAVAX to ESPRIT.

 

 

Confidential

     NOW, THEREFORE, in consideration of the above premises and the covenants contained herein, the
parties agree as follows:

ARTICLE 1.  DEFINITIONS

     As used in this Agreement, the following terms, when used with initial capital letters, shall
have the following meanings, the singular shall include the plural and vice-versa:

     1.1. “Affiliate” means any entity that directly or indirectly controls, is controlled
by, or is under common control with a Party, and for such purpose “control” shall mean (i) directly
or indirectly owning, controlling or holding more than fifty percent (50%) of the securities or
other ownership interests representing the equity, the voting stock or general partnership interest
in an entity or (ii) the possession, direct or indirect, of the power to direct or cause the
direction of the management or the policies of the entity, whether through the ownership of voting
securities, by contract or otherwise. Any such corporation, entity or business structure shall
only be considered an Affiliate for so long as such ownership or control exists.

     1.2. “Business Day” means any day other than Saturday, Sunday, holiday or any other
day on which banks in New York, New York are permitted or required to be closed. Unless otherwise
specified herein, “day” will mean calendar day.

     1.3. “Calendar Quarter” means each of the periods of time between January and March,
April and June, July and September, and October and December.

     1.4. “Calendar Year” means the period of time commencing on 1 January and ending on
the following 31 December.

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-2-

 

Confidential

     1.5. “Commercial Sale” and words of similar import means, an arm’s length transaction
and shipment by ESPRIT, its Affiliates or each of its Sublicensees of a Licensed Product to an
independent Third Party in a country of the Territory.

     1.6. “Competing Product” has the meaning set forth in Section 5.3.1 (Notice).

     1.7. “Confidential Information” has the meaning set forth in Section 6.1 (Confidential
Information).

     1.8. “Dollar” means the legal currency of the U.S.

     1.9. “Effective Date” has the meaning set forth in the first paragraph of this
Agreement.

     1.10. “ESPRIT Improvement” means any and all Improvements created, conceived or first
reduced to practice by ESPRIT, or its Affiliates, agents, subcontractors or Sublicensees, alone or
with others (excluding NOVAVAX).

     1.11. “ESPRIT Improvement Intellectual Property” means Intellectual Property in ESPRIT
Improvements, including without limitation ESPRIT Improvement Patents.

     1.12. “ESPRIT Improvement Patents” means patents and patent applications that describe
and claim ESPRIT Improvements.

     1.13. “ESPRIT Sole Technology” means Intellectual Property that is first conceived and
first reduced to practice during the term of this Agreement solely by personnel employed by or on
behalf of ESPRIT or its Affiliates, agents, subcontractors or Sublicensees.

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-3-

 

Confidential

     1.14. “ESPRIT Technology” means ESPRIT Improvement Intellectual Property, ESPRIT Sole
Technology, ESPRIT’s interest in any Joint Improvement Intellectual Property, and any other
Intellectual Property owned or controlled by ESPRIT that would, but for the license granted to
NOVAVAX in this Agreement, be infringed by NOVAVAX’s performance of its obligations under this
Agreement or the Supply Agreement.

     1.15. “FDA” means the United States Food and Drug Administration and successor bodies.

     1.16. “FD&C Act” means the United States Food, Drug and Cosmetic Act, as amended, and
the rules and regulations of the FDA promulgated thereunder.

     1.17. “Field” means the use, manufacture or sale of topically- or
transdermally-administered products containing no other active ingredient other than testosterone
for the treatment of hypoactive sexual disorder of human females.

     1.18. “First Commercial Sale” means, with respect to any Licensed Product, the first
Commercial Sale in a country of the Territory following the receipt of Regulatory Approval in such
country.

     1.19. “Fiscal Year” means the period of time commencing on the Monday following the
Sunday closest to the end of the calendar month of December and terminating on the Sunday closest
to the end of the immediately succeeding December.

     1.20. “Formulation” has the meaning set forth in Section 8.1.1 (Ownership and
Authority).

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-4-

 

Confidential

     1.21. “GAAP” means U.S. generally accepted accounting principles, consistently
applied.

     1.22. “Improvement” means any change, improvement, development, or modification of a
Licensed Product with respect to formulation technology, any component/material utilized in the
formulation technology, or the method or process of making or using a Licensed Product utilizing
the formulation technology, that (a) is made, conceived of, or reduced to practice by either Party
or their Affiliates, agents, subcontractors or Sublicensees, alone or with others, or as a result
of work performed on a Licensed Product during the term of this Agreement and (b) is covered by or
derived or resulting from the practice of Licensed Patents, patents, patent applications and other
Intellectual Property rights in or that cover any of the foregoing.

     1.23. “Improvement Patent” means patents and patent applications that describe and
claim Improvements.

     1.24. “IND” means an “Investigational New Drug” application (as defined in the FD&C
Act and applicable FDA rules and regulations) and any supporting data and information.

     1.25. “Intellectual Property” means any intellectual property rights, including
without limitation, patents, patent applications, inventions, and know-how.

     1.26. “Joint Improvement” means any and all Improvements created, conceived, or first
reduced to practice during the term of this Agreement by NOVAVAX, or its Affiliates, agents,
subcontractors or Sublicensees, and ESPRIT, or its Affiliates, agents, subcontractors or

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-5-

 

Confidential

Sublicensees. Joint Improvement shall not include any Improvement that is a NOVAVAX Improvement or
an ESPRIT Improvement.

     1.27. “Joint Improvement Intellectual Property” means Intellectual Property in Joint
Improvements.

     1.28. “Joint Improvement Patents” means patents and patent applications that describe
and claim Joint Improvements.

     1.29. “Launch” means the date of the First Commercial Sale of any Licensed Product in
the Territory.

     1.30. “Licensed Know-How” means, to the extent relating and necessary to the
manufacture of a Licensed Product, all information or special knowledge on the part of NOVAVAX as
of the Effective Date not generally known to the public, including but not limited to inventions,
discoveries, reports, protocols, processes, apparati, techniques, methods, models, screens, assays,
products, regulatory submissions, and technical information, together with all experience, data,
formulas, procedures and results, and including all chemical, pharmacological, toxicological,
clinical, analytical, quality control, and safety data (including but not limited to
data from use of the Licensed Product), and any other materials or compositions relating to
the formulation or manufacture of a Licensed Product or being useful in the manufacture, use, sale
or Registration of a Licensed Product as reasonably determined by NOVAVAX. Licensed Know-How also
includes the NOVAVAX Improvement Intellectual Property as set forth in Section 5.1.5 (NOVAVAX
Improvement Intellectual Property) hereof to the extent not disclosed in any

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-6-

 

Confidential

patent or published
patent application of the Licensed Patents; except to the extent that the disclosure of such
information or special ability is prohibited by law, rule, regulation, order, treaty, contract,
agreement, or other obligation. Licensed Know-How shall constitute Confidential Information of
NOVAVAX in accordance with Section 6.1 (Confidential Information).

     1.31. “Licensed Patent” means U.S. Patent No. 5,629,021, Canadian Patent No.
2,211,262, Mexican Patent No. 198,438, including any other of their respective counterparts in the
Territory, as well as all continuations, continuations-in-part, divisions, renewals, reissues,
reexaminations, extensions, and patents of addition and patents of importation of the foregoing
containing a Valid Claim that would be infringed by the use or sale of a Licensed Product by
ESPRIT, its Affiliates or its permitted Sublicensees, in the Territory, but for the licenses
granted herein. In addition, Licensed Patents shall include NOVAVAX Improvement Patents, NOVAVAX’s
interests in Joint Improvement Patents and any other patents owned by NOVAVAX that are necessary
for ESPRIT to practice the patents described in the preceding sentence.

     1.32. “Licensed Product” means the topically- or transdermally-administered product
and containing no other active ingredient other than testosterone for the treatment of hypoactive
sexual disorder of human females that is currently in clinical trials under NOVAVAX’s IND No.
63957. Licensed Products include Improvements made by NOVAVAX related to, without limitation,
formulation and/or packaging for the Licensed Product.

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-7-

 

Confidential

     1.33. “Licensed Technology” means Licensed Patents, any patent applications and
Licensed Know-how.

     1.34. “NDA” means a “New Drug Application” (as defined in 21 C.F.R. Part 314).

     1.35. “Net Sales” means, on a country-by-country basis (a) for any bona fide arm’s
length transaction in which Licensed Products are Commercially Sold separately by ESPRIT, its
Affiliates, or its Sublicensees to Third Parties (rather than bundled with any other products or
services), the amount invoiced for the sale of Licensed Products in finished packaged form, and
(b) for all other transactions in which Licensed Products are sold, used or otherwise disposed of
by ESPRIT, its Affiliates or its Sublicensees (including in barter or similar transactions, or
transactions that are not at arm’s length to a Third Party, or transactions in which Licensed
Products are not sold separately), the average invoiced sales price for Products in arms-length
transactions in the applicable country; less, in the case of clause (a) and (b) above (i) all
normal and customary trade and quantity discounts, (ii) allowances, chargebacks, wholesaler fees
and deductions, retailer fees and deductions, rebates, including government and managed care
rebates, and credits determined in accordance with GAAP, and returns and replacements determined in
accordance with GAAP, less any freight charges paid by Third Parties for delivery
and less excise, value added and other taxes and or/duties applicable to sales of Licensed
Products which the selling party has to pay or absorb on such sales. Further, Net Sales shall not
include normal and customary promotional samples, including, subject to the foregoing, any samples
affixed to or accompanying other products of ESPRIT or any of its Affiliates, coupons or other
promotional incentives.

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-8-

 

Confidential

     1.36. “NOVAVAX Improvement” means any and all Improvements created, conceived or first
reduced to practice by NOVAVAX, or its Affiliates, agents, subcontractors or Sublicensees, alone or
with others (excluding ESPRIT).

     1.37. “NOVAVAX Improvement Intellectual Property” means Intellectual Property in
NOVAVAX Improvements.

     1.38. “NOVAVAX Improvement Patents” means patents and patent applications that
describe and claim NOVAVAX Improvements.

     1.39. “Person” means an individual, corporation, partnership or other entity.

     1.40. “PDUFA” means the Prescription Drug User Fee Act, as amended, and the rules and
regulations of the FDA promulgated thereunder.

     1.41. “Phase II Clinical Study” means a human clinical study on a sufficient number of
patients designed to establish the optimal dose of a pharmaceutical product to be used in a Phase
III Clinical Study of such product and to support Registrations and Regulatory Approval of such
product. A Phase II Clinical Study shall be deemed to have commenced when the first patient is
dosed in such Phase II Clinical Study. A Phase II Clinical Study shall also include any
Phase II/Phase III study conducted in lieu of a Phase II study, whether or not such study is a
traditional Phase III study.

     1.42. “Phase III Clinical Study” means a human clinical study on a sufficient number
of patients that is designed to establish that a pharmaceutical product is safe and efficacious for
its intended use, and to define warnings, precautions and adverse reactions that are associated

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-9-

 

Confidential

with the product in the dosage ranges to be prescribed and to support Registrations and Regulatory
Approval of such product or label expansion of such product. A Phase III Clinical Study shall be
deemed to have commenced when the first patient is dosed in such Phase III Clinical Study.

     1.43. “Registration” means a filing with a governmental authority for the purpose of
obtaining legal and Regulatory Approval to conduct clinical trials for a product or to commence
selling and marketing a product, including an NDA or IND filing or its equivalent in the Territory,
including, without limitation, pricing and reimbursement approval.

     1.44. “Regulatory Approval” means the license or marketing approval necessary as a
prerequisite for marketing and selling a Licensed Product in a particular country in the Territory.

     1.45. “Steering Committee” means the body organized and acting pursuant to Section
3.1.2 (Steering Committee) hereof.

     1.46. “Sublicense” means a sublicense of the license to ESPRIT under Section 2.1
(License Under NOVAVAX Technology) granted by ESPRIT in accordance with the terms of this
Agreement. When used as a verb “Sublicense” means to grant a Sublicense.

     1.47. “Sublicensee” means a Person who has been granted a Sublicense by ESPRIT in
accordance with the terms of this Agreement.

     1.48. “Supply Agreement” means a separate agreement to be executed and delivered
concurrently with this Agreement under which NOVAVAX shall supply Licensed Product to ESPRIT.

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-10-

 

Confidential

     1.49. “Territory” means the United States, its territories (including Puerto Rico),
Mexico and Canada.

     1.50. “Third Party” means any Person other than a Party to this Agreement or an
Affiliate of a Party or Sublicensee.

     1.51. “Valid Claim” means a claim or pending claim in any unexpired, enforceable,
issued patent, or pending patent application within the Licensed Patent or Improvement Patent which
has not been held invalid by a non-appealed or unappealable decision by a court or other
appropriate body of competent jurisdiction, and which is not admitted to be invalid through
disclaimer or dedication to the public.

     1.52. “Work Plan” means the work plan for the Licensed Product to be developed within
seventy-five (75) days of the Effective Date under this Agreement in the Field, as such work plan
may be modified or updated from time to time in accordance with Section 3.1.1 (Development
Program).

     1.53. “Year” shall mean the period of time commencing on the calendar day of the First
Commercial Sale of a Licensed Product in any country in the Territory and ending three hundred and
sixty four (364) days thereafter.

ARTICLE 2.  GRANT OF RIGHTS

     2.1. License Under NOVAVAX Technology. Subject to the terms and conditions hereof,
NOVAVAX hereby grants to ESPRIT, commencing on the Effective Date, an exclusive

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-11-

 

Confidential

license under the
Licensed Technology to make and have made, import, use, sell, offer for sale, and have sold the
Licensed Product in the Territory in the Field.

     2.2. Sublicenses. ESPRIT shall have the right to sublicense commencing on the
Effective Date the rights granted under Section 2.1 (License Under NOVAVAX Technology) of this
Agreement on terms substantially similar to those contained herein to a controlled Affiliate of
ESPRIT and to non-Affiliated Third Parties, provided that any such sublicense to non-Affiliated
Third Parties would require the prior written approval of NOVAVAX which will not be unreasonably
withheld or delayed; and provided, further that ESPRIT shall require its permitted Sublicensees to
comply with all of the obligations of ESPRIT contained in this Agreement and ESPRIT shall be
responsible for the performance by such Sublicensees of such obligations.

     2.3. License under ESPRIT Technology. ESPRIT hereby grants to NOVAVAX a royalty-free,
exclusive license, except as to ESPRIT, its Affiliates and Sublicensees, under the ESPRIT
Technology solely in order to permit NOVAVAX to perform the services and/or obligations of NOVAVAX under this Agreement and the Supply Agreement. In addition, ESPRIT
hereby grants to NOVAVAX an exclusive, perpetual, irrevocable, worldwide, paid-up, royalty-free
license, with rights to sublicense, under all of ESPRIT’s rights under ESPRIT Improvement
Intellectual Property and ESPRIT’s interests in Joint Improvement Intellectual Property for use
outside the Field.

     2.4. Product Quality. ESPRIT shall assure at all times that the quality of the
Licensed Products is of a standard of quality consistent pharmaceutical industry standards in the
U.S.

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-12-

 

Confidential

ESPRIT additionally shall assure at all times that the Licensed Products are distributed,
marketed, advertised, promoted and sold in accordance with all applicable laws and regulations. In
addition, after termination or expiration of the Supply Agreement, ESPRIT shall assure at all times
that the Licensed Products are sourced, manufactured, and labeled in accordance with all applicable
laws and regulations.

     2.5. No Implied Rights. Except as otherwise expressly provided in this Agreement,
under no circumstances shall a Party hereto, as a result of this Agreement, obtain any ownership
interest or license in or other right to any technology, know-how, patents, patent applications,
products, or biological materials of the other Party, including, but not limited to, items owned,
controlled or developed by the other Party, at any time pursuant to this Agreement. This Agreement
does not create, and shall under no circumstances be construed or interpreted as creating, an
obligation on the part of either Party to grant any license to the other Party other than as
expressly set forth herein. Any further contract or license agreement between the Parties shall be
in writing.

     2.6. Reserved Interests. All rights and interests not expressly granted to ESPRIT are
reserved by NOVAVAX (the “Reserved Interests”) for itself, its Affiliates and partners (other than
ESPRIT) and other licensees and Sublicensees, including, but not limited to, the rights to use and
grant licenses under the Licensed Technology or any other technology or intellectual property owned
or controlled by NOVAVAX to make, have made, use, offer to sell, sell, have sold and import
products (other than a license under Licensed Technology for Licensed Products in the Field, for so
long as ESPRIT has an exclusive license under Licensed Technology for

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-13-

 

Confidential

Licensed Products in the
Field). It shall not be a breach of this Agreement for NOVAVAX, acting directly or indirectly, to
exploit its Reserved Interests in any manner anywhere in the Territory, provided, however, that
under no circumstances shall NOVAVAX utilize its Reserved Interests to directly or indirectly make,
have made, use, offer to sell, sell, have sold or import Licensed Products or related Improvements
in the Territory in the Field during the term of this Agreement.

 ARTICLE 3. LICENSED PRODUCT DEVELOPMENT AND COMMERCIALIZATION

     3.1. Development.

     3.1.1. Development Program. ESPRIT shall be solely responsible for developing and
obtaining Regulatory Approval for the Licensed Product in the Field, at ESPRIT’s sole cost
and expense. NOVAVAX shall cooperate to the extent necessary in support of ESPRIT’s efforts
to obtain such Regulatory Approval. ESPRIT shall develop and receive Regulatory Approval for
the Licensed Product in the Territory and shall engage in a development program (the
“Development Program”) to develop and obtain
Regulatory Approval the Licensed Product for the Field in accordance with the Work Plan.
The Parties shall develop a mutually-agreeable commercially reasonable and detailed work
plan (the “Work Plan”) setting forth development timelines and budgets for the Development
Program within *** of the Effective Date. Without limiting the generality of the foregoing,
ESPRIT shall use commercially reasonable efforts to conduct pre-clinical and clinical trials
for the Licensed Product, file Registrations and diligently pursue Regulatory Approvals of
the Licensed Product in the Territory, and in such regard

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-14-

 

Confidential

shall devote such resources and
exercise such diligent efforts as are reasonable in view of the size of the market and
potential market for the Licensed Products and in no event less than those devoted by
companies of similar size and type for products with the same commercial potential, all
within the agreed upon timelines set forth in the Work Plan. In conducting the Development
Program, ESPRIT shall consult with NOVAVAX on a regular basis in order to proceed with the
development efforts as quickly as practicable. Any material change in the Work Plan shall
be mutually agreed upon by NOVAVAX and ESPRIT.

     3.1.2. Development Milestone. Without limiting the generality of Section 3.1.1
(Development Program), and subject to the occurrence of a Force Majeure Event (as defined in
section 12.1), NOVAVAX shall be entitled to terminate this Agreement pursuant to Section 9.2
(Termination for Breach) if ESPRIT has failed to meet any of the following development
milestones, as such may be extended pursuant to the then current Work Plan or other mutual
agreement of the parties, not to be unreasonably withheld or delayed (the “Development
Milestones”), provided further, that, for the avoidance of
doubt, any such failure will be subject to a cure period prior to termination in
accordance with Section 9.2:

     (a) Submission of a Phase II clinical study briefing package to the FDA within
*** from the Effective Date;

     (b) Administration of the first dose of the test product in humans within ***
from a successful FDA meeting including permission to a start a Phase

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-15-

 

Confidential

II double-blind dose ranging study (“Phase II Study”) with FDA agreement on the
measuring instrument to determine patient reported outcomes;

     (c) Summarize Phase II Study results and select a dose and submit a protocol to
the FDA for a Phase III clinical study within *** of the date of last patient
completing the double- blind portion of the Phase II Study; and

     (d) Administration of the first dose of test product in humans for a randomized
double-blind placebo controlled Phase III pivotal trial within *** from the date of
approval of a special protocol assessment.

Notwithstanding the foregoing provisions of this Section 3.1.2, the Parties acknowledge that (i)
there is uncertainty in the scientific community generally regarding the efficacy outcome
measurements and methodology for products for the treatment of sexual disorder in human females
and also with respect to what FDA will find acceptable, and designing such a study may take
longer than expected, despite ESPRIT’s commercially reasonable efforts, and (ii) the FDA’s
actions or inaction may be beyond the reasonable control of ESPRIT that make it
impractical for ESPRIT to obtain one or more Development Milestones despite ESPRIT’s
commercially reasonable efforts. If the Development Milestones have not been achieved due to
either (x) delays in submitting the Phase II Clinical Study briefing package to the FDA due to
ongoing development and implementation of efficacy outcome measurements and methodology or (y)
any action or inaction by the FDA, but ESPRIT has continued to use commercially reasonable
efforts to develop and obtain Regulatory Approval for the Licensed Product in accordance with
Section 3.1.1 (Development Program) and if the Development

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-16-

 

Confidential

Program is still ongoing and
progressing to completion within a reasonable timeframe, then NOVAVAX shall not be entitled to
terminate this Agreement because of such failure, and the Parties shall negotiate in good faith
to extend the Development Milestone deadlines as is reasonable in light of such continued
development or FDA action or inaction as the case may be. In the event the parties are
unsuccessful in re-negotiating the Development Milestones, then either Party shall be entitled
to Terminate this Agreement on *** written notice to the other Party and in the event of such
Termination under this Section 3.1.2, the provisions of Section 9.4 shall apply .

     3.1.3. Steering Committee. To plan, manage and oversee work on the Development Program
and to approve, update and modify the Work Plan as may be necessary, NOVAVAX and ESPRIT shall
promptly after the Effective Date organize a steering committee (the “Steering Committee"),
consisting of three (3) members from NOVAVAX and three (3) members from ESPRIT. ESPRIT shall
have the right to appoint one of its members to be the chairperson of the Steering Committee.
The Parties shall each have the right, upon notifying the other, to change its members of
the Steering
Committee at any time during the Term of this Agreement and to invite such non-Steering
Committee members to a meeting of the Steering Committee as such Party shall reasonably
determine. The Parties shall hold meetings of the Steering Committee as mutually agreed by
the Parties (but in no event less than once per Calendar Quarter) to review the Development
Program and to discuss future activities under this Agreement; provided, however, that each
Party shall have the right to call additional meetings of the Steering Committee in order to
discuss new material events upon twenty (20) days’ prior

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-17-

 

Confidential

written notice (one of which may
require an in person meeting). Not later than ten (10) days prior to each of the four
regularly scheduled Steering Committee meetings, ESPRIT shall prepare a report for the
Steering Committee detailing the progress of the Development, Program including successes,
difficulties, milestone achievements and a comparison of the status of the Development
Program as compared to the timeline contained in the Work Plan. Such report shall also
contain any recommendations for updates or modifications to the Work Plan. Consultants and
non-Steering Committee member employees of the Parties may attend meetings of the Steering
Committee as required to further the Development Program only upon written notice to the
Party not bringing the consultants and non-Steering Committee members. Unless otherwise
mutually agreed by the Parties, the Steering Committee meetings shall be in-person and shall
alternate between ESPRIT’s designated facility and NOVAVAX’s designated facility. The first
meeting shall be held at ESPIRT’s designated facility. Minutes of all such meetings setting
forth decisions of the Steering Committee relative to the Development Program shall be
prepared. Responsibility for the minutes shall alternate
between NOVAVAX and ESPRIT, with NOVAVAX being responsible for the minutes of the first
meeting; provided that minutes shall not become official until approved by
each of the Parties. Any vote of the Steering Committee shall include at least one (1)
representative of each of NOVAVAX and ESPRIT. The Steering Committee shall make all
decisions only by consensus. Any non-concurrence of the Steering Committee relating to any
issue, question or dispute shall be elevated to the Head of Research and Development of
ESPRIT and to the Head of Research and Development of NOVAVAX

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-18-

 

Confidential

for resolution and failing
resolution by such individuals, to the President and Chief Executive Officer of NOVAVAX and
President and Chief Operating Officer of ESPRIT for resolution, recognizing that, in the
event of continuing disagreement, the final decision and ultimate resolution shall rest with
ESPRIT.

     3.1.4. Written Records. ESPRIT shall record, to the extent practical, all technical
information relating to its research and development activities under the Development Program
in written form, which writing shall be signed, dated and witnessed, consistent with ESPRIT’s
standard practices and what is normal and customary in the industry in the United States or
as may be required by applicable law or regulation. To the extent practical, such written
records shall be kept separately from written records documenting ESPRIT’s other research and
development. All such written records shall be maintained in a form that ESPRIT reasonably
believes is sufficient to satisfy regulatory authorities. Each Party shall require its
employees and consultants to disclose to it any discoveries or inventions relating to
Licensed Product and made in the course of its activities under the Development Program in
writing promptly after conception, and each
Party shall, subsequent to any such disclosures to it by its employees or consultants,
promptly disclose such discoveries and inventions to the other Party. Without limiting the
generality of the foregoing, not later than ten (10) days prior to each of the four regularly
scheduled Steering Committee meetings of each Calendar Year during the development of the
Licensed Products, ESPRIT shall prepare and submit to the Steering Committee a report
summarizing all such development activities and identifying all significant results or
developments during such period. Such quarterly reports shall include, without

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-19-

 

Confidential

limitation, a
description of any significant deviations from the Work Plan and proposed actions with
respect to such deviations. Such reports shall be subject to the confidentiality provisions
of ARTICLE 6 (Confidentiality and Publicity) hereof.

     3.1.5. Development Responsibilities. The Parties currently contemplate that ESPRIT
shall be solely responsible for the Development Program. If during the course of the
Development Program, the Steering Committee unanimously agree that it would be advantageous
for NOVAVAX to assume responsibility for some portion of the Development Program, at ESPRIT’s
expenses, including labor and administrative charges, then the Parties will agree upon a
commercially reasonable procedure for ESPRIT to reimburse NOVAVAX for its costs and expenses
in performing such work. NOVAVAX will also be bound to maintain records relating to such
work being delegated to NOVAVAX herein and such records will be made available to ESPRIT on a
timely basis upon request.

     3.2. Regulatory Approvals.

     3.2.1. Responsibility for Registration During Development. Except as provided in
Section 3.2.2 (Transfer of IND to ESPRIT), ESPRIT shall be responsible for the preparation,
filing and prosecution of all Registrations in the Territory, including, without limitation,
U.S. Registrations with the FDA, which are required to commercially sell or use the Licensed
Products in the Territory. ESPRIT shall use commercially reasonable efforts to seek to
obtain Regulatory Approvals for the Registrations in accordance with the Work Plan. This
will include, without limitation, maintaining IND

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-20-

 

Confidential

No. 63957 (once such IND is transferred to
ESPRIT in accordance with Section 3.2.2 (Transfer of IND to ESPRIT)), periodic FDA
consultations during the clinical development of the Licensed Product, and filing and
maintaining the NDA for the Licensed Product. With regard to the U.S., ESPRIT and NOVAVAX
shall be entitled to interface with the FDA relating to clinical trials and other aspects of
the Licensed Product’s development and commercialization; provided that NOVAVAX shall be the
exclusive interface with the FDA relating to the manufacture of the Licensed Product until
the transfer of the IND to ESPRIT. ESPRIT shall promptly provide NOVAVAX with a copy of any
Registrations that have been or are proposed to be filed by ESPRIT with the FDA or any
comparable regulatory authority in the Territory, as well as copies of correspondence between
NOVAVAX and the FDA or such other regulatory authority relating to the Licensed Product.
ESPRIT will be responsible for all costs of insurance that are customary and, in NOVAVAX’s
reasonable judgment, are necessary, in connection with clinical trials of the Licensed
Product. Maintenance of the Registrations and Regulatory Approvals will be ESPRIT’s sole
responsibility. Without limiting the
generality or effect of the foregoing, ESPRIT will be responsible for all PDUFA fees,
including establishment fees and product fees, associated with any NDA for the Licensed
Product. However the establishment fees will be allocated on a pro rata basis agreed upon by
the parties in the event other FDA approved product(s) are manufactured by Novavax at the
Cardinal Red Lion facility. ESPRIT shall also provide NOVAVAX with reports concerning the
status of the Registrations for the Licensed Products in the Territory and

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-21-

 

Confidential

the estimated date
of receipt of final Regulatory Approval of the Registrations of the Licensed Products.

     3.2.2. Transfer of IND to ESPRIT. At a commercially reasonably time approved by the
Steering Committee given NOVAVAX’s responsibilities for initial chemistry, manufacturing and
controls under the Supply Agreement, each Party shall, using commercially reasonable efforts,
take all steps necessary to transfer IND No. 63967 from NOVAVAX to ESPRIT, at ESPRIT’s cost
and expense, including, without limitation, filing of any documents or instruments with the
FDA required to effect such transfer. Without limiting the generality of the foregoing, at
the direction of the Steering Committee, NOVAVAX shall provide ESPRIT with a letter addressed
to the FDA authorizing and requesting IND No. 63967 be transferred, in its entirety, to the
name of ESPRIT, and ESPRIT shall send a letter to the FDA accepting the IND. ESPRIT shall,
thereafter, be responsible for fulfilling any and all regulatory requirements with respect to
the Licensed Products that are imposed as the owner thereof including, without limitation,
the filing of documents and payment of fees to the FDA in order to affect the transfer of
such IND.

     3.2.3. Access to Data and Regulatory Approvals and Registrations. NOVAVAX will be
entitled to copy and reference any Registration or Regulatory Approval (including any NDA)
and any safety database or other safety information related to the Licensed Products for any
purpose, except that NOVAVAX will not use such information with respect to the development of
a Licensed Product in the Territory in the

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-22-

 

Confidential

Field so long as the exclusive license granted in
Section 2.1 (License Under NOVAVAX Technology) remains in effect. ESPRIT will be entitled to
copy and reference for any purpose any Registration or Regulatory Approval and any safety
database or other safety information related to the Licensed Products as being developed,
marketed and sold by NOVAVAX or its designee outside the Territory.

     3.3. Commercialization. ESPRIT shall control and make all decisions regarding the
strategy and tactics of marketing, selling and otherwise commercializing the Licensed Product in
the Territory, including, without limitation, the methods of sale and distribution, organization
and management of sales and marketing, appointment of distributors, and other terms and conditions
of such sales and marketing, and shall exercise commercially reasonably efforts to market, sell and
otherwise commercialize the Licensed Product in the Territory. Upon the Launch of a Licensed
Product in a country of the Territory, ESPRIT, either itself or through its Affiliates or
Sublicensees, shall market, distribute and sell the Licensed Products in such country of the
Territory and shall exercise such diligence in this regard as shall be commercially reasonable in
light of the size of the market and potential market for the Licensed Product and in a manner
consistent with which it markets other ESPRIT products of comparable market size in such country of
the Territory. ESPRIT shall bear all expenses relating to the marketing, selling and
other commercialization of License Products in the Territory, including any post-Regulatory
Approval clinical studies, such as any “Phase IV” or lowest effective dose study; provided that
NOVAVAX will be entitled to review and provide comments relating to the protocols of any such
study.

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-23-

 

Confidential

     3.3.1. Medical Inquiries. ESPRIT shall respond to medical questions or inquiries
relating to the Licensed Product and shall instruct its sales force to direct medical
inquiries either to its own medical personnel or to the ESPRIT toll-free number referred to
in Section 3.3.2 (Toll-Free Number), within a reasonable time from the Effective Date.
ESPRIT shall designate an individual to serve as medical liaison in order to ensure
consistency in the handling of medical inquiries. The medical liaison will regularly review
Licensed Product inquiries and responses and will also be available for responding to
non-routine inquiries should these arise.

     3.3.2. Toll-Free Number. ESPRIT shall maintain a toll-free telephone number to provide
information in response to inquiries from health care professionals and consumers. This
number shall be noted in all appropriate advertising and promotional materials, except that
NOVAVAX may, at its own option and expense, use a different number in advertising and
promotional materials that it develops for use outside of the Territory.

ARTICLE 4. PAYMENTS

     4.1. Development Milestone Payments. In partial consideration of the license granted
hereunder, ESPRIT shall make the following one time, nonrefundable, non-creditable payments in
Dollars to NOVAVAX by wire transfer within *** of the satisfaction of each of the following
conditions:

	 	 	 	 	 
	Condition	 	Payment	 
	***
	 	 	$***	 
	The earlier of (a) *** or (b) ***
	 	 	$***	 

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-24-

 

Confidential

     4.2. Royalties. ESPRIT will, or will cause its designated Affiliates, to pay NOVAVAX
quarterly royalties on the Net Sales of Licensed Products in the Territory during the term of this
Agreement, subject to Section 4.3 (Excluded Sales) below. Such royalty payments shall be based upon
Net Sales of Licensed Products according to the following schedule:

	 	 	 	 	 
	 	 	Percentage of Net Sales for
	Country	 	Calendar Year
	United States
	 	 	*** 	%
	Canada
	 	 	***	%
	Mexico
	 	 	*** 	%

     4.3. Excluded Sales. No royalties due under this ARTICLE 4 (Payments) shall be
payable on sales transactions as among ESPRIT, any of its Affiliates and Sublicensees. The final
vendee sale to a Third Party alone shall be used for the purposes of determining the royalty
payments due hereunder. Only one royalty payment shall be payable on the sale of each Licensed
Product. Licensed Products shall be sold only for cash consideration and there shall be no
discounting of price to the disadvantage of the price of Licensed Products that are included in or
made part of any bundling of Licensed Products with any existing or future product(s) of ESPRIT or
its Affiliates as part of a sale to Third Parties.

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-25-

 

Confidential

     4.4. Royalty Period. ESPRIT shall not be obligated to pay any royalty payments based
upon sales of a given Licensed Product in a country of the Territory after the expiration of the
last to expire Licensed Patent or Improvement Patent having at least one (1) Valid Claim that would
be infringed by the sale of that Licensed Product by ESPRIT, its Affiliates or its Sublicensees in
that country but for the licenses granted herein.

     4.5. Payments. All royalties shall be calculated and payable on a Calendar Quarter
basis as of the end of the each Calendar Quarter, and royalties shall be paid within *** days
following the end of such Calendar Quarter. All royalties shall be calculated on a Licensed
Product by Licensed Product basis. Each royalty payment and Milestone Payment shall be accompanied
by a written report indicating the amount of Net Sales during such Calendar quarter or applicable
period together with a calculation of the royalties and Sales Milestone Payments due. ESPRIT shall
deliver the written report for each such Calendar Quarter or applicable period, regardless of
whether when any royalty payments or Milestone Payments are required to be paid in that Calendar
Quarter or applicable period, commencing in the first Calendar Year following Launch.

     4.6. Audits. NOVAVAX shall have the right, at its own expense, for the period during
which a royalty or Milestone Payment is due to NOVAVAX, to have a firm of independent certified
public accountants, to whom ESPRIT has no reasonable objection and subject to customary
confidentiality restrictions, solely to examine the relevant books and records of account of ESPRIT
relating to the Licensed Product during reasonable business hours and no more than *** during each
Fiscal Year, to determine whether appropriate payment (including,

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-26-

 

Confidential

without limitation, payment
pursuant to Sections 4.1 (Development Milestone Payments) and 4.2 (Royalties)) has been made by
ESPRIT hereunder. The accountant shall disclose to NOVAVAX only information relating to the
accuracy of the royalty and Milestone Payment reports and the royalty payments and Milestone
Payments made according to this Agreement. The information received by the accountant, except for
information necessary for disclosure to NOVAVAX to establish the accuracy of such reports, shall be
held confidential. If such accounting firm concludes that additional royalties or Milestone
Payments were owed during such period, ESPRIT shall pay the additional royalties within thirty (30)
days of the date NOVAVAX delivers to ESPRIT such accounting firm’s written report so concluding.
ESPRIT will be provided an opportunity to review the findings of the accountant during the
aforementioned thirty (30) period to validate such findings. If the amount of such additional
royalties or Milestone Payments owed exceeds *** of the amount of royalty payments or Milestone
Payments actually made by ESPRIT for such period, ESPRIT shall reimburse NOVAVAX for the
commercially reasonable fees and expenses of the accounting firm incurred in the conduct of the
applicable audit.

     4.7. Currency Conversion. The remittance of Milestone Payments or royalties payable
on sales outside the U.S. will be payable to NOVAVAX in Dollars according to the
official rate of exchange of the currency of the country from which the royalties are payable
as quoted by The Wall Street Journal, New York edition, for the last day of the Calendar Quarter or
other applicable period for which the royalty payment is made. If the transfer or the conversion
into U.S. Dollars in any such instance is not lawful or possible, the payment of such part of the
Milestone Payment of royalties as is necessary shall be made by the deposit thereof, in whatever
currency is allowable and acceptable by NOVAVAX, to the credit and account of NOVAVAX or

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-27-

 

Confidential

its
nominees in any commercial bank or trust company of its choice located in that country. ESPRIT
shall give prompt notice of such deposit to NOVAVAX.

     4.8. Payment Mechanics. All royalties, Milestone Payments and other payments required
under this Agreement shall be paid in Dollars in accordance with the instructions provided by
NOVAVAX in immediately available funds by wire transfer to a bank or other institution designated
in writing by NOVAVAX from time to time.

     ARTICLE
5. INTELLECTUAL PROPERTY AND REGULATORY MATTERS

     5.1. Intellectual Property Ownership.

     5.1.1. Existing Intellectual Property. Any Intellectual Property rights owned or
controlled by either Party prior to the Parties entering into this Agreement shall remain the
property of such Party, subject only to the rights and licenses granted herein.

     5.1.2. NOVAVAX Intellectual Property. Any Intellectual Property that is first conceived
and first reduced to practice during the term of this Agreement solely by
personnel employed by or on behalf of NOVAVAX shall remain the property of NOVAVAX,
subject to the rights and licenses granted herein.

     5.1.3. ESPRIT Sole Technology. Any Intellectual Property that is first conceived and
first reduced to practice during the term of this Agreement solely by personnel employed by
or on behalf of ESPRIT shall remain the property of ESPRIT, subject to the rights and
licenses granted herein (“ESPRIT Sole Technology”).

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-28-

 

Confidential

     5.1.4. Joint Intellectual Property. Any Intellectual Property that is first conceived
or first reduced to practice during the term of this Agreement by personnel employed by or on
behalf of ESPRIT and personnel employed by or on behalf of NOVAVAX (other than the
Intellectual Property described in Section 5.1.2 (NOVAVAX Intellectual Property) and Section
5.1.3 (ESPRIT Sole Technology)) shall be and shall remain the joint property of NOVAVAX and
ESPRIT, subject to the rights and licenses granted herein (“Joint Intellectual Property”).
The parties agree to keep the Joint Intellectual Property in confidence on a basis consistent
with ARTICLE 6 (Confidentiality and Publicity) and not to publicly disclose the same except
in accordance with ARTICLE 6 (Confidentiality and Publicity).

     5.1.5. NOVAVAX Improvement Intellectual Property. NOVAVAX Improvement Intellectual
Property shall constitute Licensed Technology throughout the term of this Agreement to the
extent that such Intellectual Property is relevant to the use, sale or Registration of a
Licensed Product and to the extent that the licensing of such Intellectual Property by
NOVAVAX to ESPRIT pursuant to the terms of this Agreement
would not be prohibited by law, rule, regulation, order, treaty, contract, agreement, or
other obligation.

5.2. Patent Prosecution.

     5.2.1. Generally. Subject to Section 5.2.4 (Abandoned Patent Applications) of this
Agreement, NOVAVAX shall have sole authority and agrees to prosecute or cause to be
prosecuted to allowance or final rejection the patent applications (including any reissue

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-29-

 

Confidential

patent applications or reexamination patent applications) included in the Licensed
Patents that are owned or controlled by NOVAVAX, in whole or in part, including the Joint
Improvement Intellectual Property (hereinafter collectively “Patent Applications”), in the
countries in which the Licensed Patents are being prosecuted or maintained as of the
Effective Date. NOVAVAX shall issue as a patent each such Patent Application prosecuted to
allowance at NOVAVAX’s sole expense. NOVAVAX shall pay all attorneys fees and other costs
associated with the preparation, filing, and prosecution of such Patent Applications in the
Territory included in the Licensed Patents.

     5.2.2. Copies. NOVAVAX agrees to promptly provide (if not already provided and on an
ongoing basis, as the case may be) ESPRIT with copies of:

     (a) All Patent Applications included in the Licensed Patents;

     (b) All prior art searches it has performed (or has had performed) related to
such Patent Applications; and

     (c) All correspondence to and from the U. S. Patent and Trademark Office and
foreign patent offices relating to such Patent Applications.

     5.2.3. Comments by ESPRIT. ESPRIT shall have the right to consult with NOVAVAX from
time to time and on a reasonable basis regarding the content of the Patent Applications
included in the Licensed Patents, as well as the prior art searches and correspondence
related thereto, and to comment thereon. NOVAVAX shall consider all such comments offered by
ESPRIT, it being agreed, however, that all final decisions

Novavax
Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-30-

 

Confidential

respecting conduct of the prosecution of said patent applications shall rest solely in
the discretion of NOVAVAX.

     5.2.4. Abandoned Patent Applications. NOVAVAX shall promptly notify ESPRIT in the event
NOVAVAX decides at any time to abandon or discontinue prosecution of any one or more of the
Patent Applications included in the Licensed Patents. Such notification will be given as
early as possible which in no event will be less than forty-five (45) days prior to the date
on which such Patent Application(s) will become abandoned. ESPRIT shall have the option,
exercisable upon written notification to NOVAVAX, to assume full responsibility for the
prosecution of the affected Patent Application(s), in which event such affected Patent
Application(s) shall, at ESPRIT’s option, be promptly exclusively licensed royalty-free to
ESPRIT and its Sublicensees to make and have made, import, sell, offer to sell, and have sold
Licensed Product in the Territory in the Field.

     5.2.5. Maintenance Fees. NOVAVAX shall pay all official taxes, annuities and fees
required to keep in force all Patent Applications and patents, which are included in the
Licensed Patents, and shall submit evidence, upon written request, to ESPRIT that said
government fees have been timely paid. In the event NOVAVAX decides not to pay the
maintenance fee due on any one or more of said patents or Patent Applications, NOVAVAX will
give ESPRIT written notice of such decision at least sixty (60) days in advance of the
payment date. ESPRIT shall thereupon have the option to pay the maintenance fees due on the
affected patents or Patent Applications, in which case the

Novavax
Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-31-

 

Confidential

affected Patent(s) or Patent Application(s) shall, at ESPRIT’s option, be promptly
exclusively licensed on an exclusive, royalty free, perpetual and fully paid up basis to
ESPRIT to make and have made, import, sell, offer to sell, and have sold Licensed Product in
the Territory in the Field.

     5.2.6. Disclosure. Each Party shall promptly disclose to the other any Improvements
made, conceived or reduced to practice by the disclosing Party or its Affiliates, agents,
subcontractors or Sublicensees.

     5.3. Enforcement of Patents

     5.3.1. Notice. If, during the term of this Agreement, NOVAVAX or ESPRIT becomes aware
of infringing sales of product in the Field competitive with Licensed Products by a Third
Party in a given Calendar Quarter in a country of the Territory that are greater than *** of
ESPRIT’s Commercial Sales of such Licensed Products, by Dollar or equivalent legal currency
of the given country in the Territory, of Licensed Products in the Field in the same country
of the Territory and in the same Calendar Quarter (a
“Competing Product”) that constitute
infringement by a Third Party of any issued patent included in the Licensed Patents, that
Party shall promptly notify the other Party in writing to that effect. ESPRIT shall have the
right, but not the obligation, to bring suit against any infringer of a patent relating at
its own cost and expense.

     5.3.2. NOVAVAX’S Initial Right. NOVAVAX shall have the initial right, but not the
obligation, to initiate or prosecute an infringement or other appropriate suit or

Novavax
Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-32-

 

Confidential

action against any Third Party infringer of a Licensed Patent at its own expense.
ESPRIT has the right to join such suit or action at its own expense. If, (a) after the
expiration of ninety (90) days from said notice, NOVAVAX has not obtained a discontinuance of
such infringement or brought suit against the Third Party infringer, and (b) the infringing
product is a Competing Product, ESPRIT shall have the right, but not the obligation, to bring
suit (at ESPRIT’S sole expense) against such Third Party infringer, provided that if NOVAVAX
is joined to the suit, NOVAVAX will pay for its own litigation expenses.

     5.3.3. Recovery. If, prior to the expiration of ninety (90) days from given notice
under Section 5.3.1 (Notice), NOVAVAX obtains a discontinuance of such infringement or brings
suit against the Third Party infringer, and ESPRIT does not join the suit, then NOVAVAX shall
retain all damages or other monies awarded or received in settlement of such suit. ESPRIT
will cooperate with NOVAVAX in any such suit and shall have the right to consult with NOVAVAX
and be represented by its own counsel at its own expense. If, prior to the expiration of
ninety (90) days from given notice under Section 5.3.1 (Notice), NOVAVAX brings suit against
the Third Party infringer, and ESPRIT exercises its right to join the suit, then each Party
shall have the right to be represented by independent counsel in such litigation at its own
expense and neither Party shall incur any liability to the other Party as a consequence of
such litigation or any unfavorable decision resulting therefrom, including any decision
holding the patent invalid or unenforceable. Furthermore, any amounts recovered as a result
of any infringement action taken by the Parties hereunder shall be split equally.

Novavax
Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	
	 	 

-33-

 

Confidential

     5.3.4. ESPRIT’s Second Right. If, after the expiration of said ninety (90) days from
the date of given notice under Section 5.3.1 (Notice), NOVAVAX has not obtained a
discontinuance of such infringement by a Competing Product or brought suit against such Third
Party infringer, and ESPRIT decides to exercise its right, after such ninety (90) notice
period, to bring suit against such infringer and join NOVAVAX as a party plaintiff, then
NOVAVAX will reasonably cooperate with ESPRIT in any suit for infringement of a patent of the
Licensed Patents brought by ESPRIT against a Third Party, and shall have the right to consult
with ESPRIT and to participate in and be represented by independent counsel in such
litigation at its own expense. Neither Party shall incur any liability to the other as a
consequence of such litigation or any unfavorable decision resulting therefrom, including any
decision holding the patent invalid or unenforceable. Furthermore, any amounts recovered as
a result of any infringement action taken by the Parties hereunder shall be split equally.

     5.3.5. Settlement. Neither NOVAVAX nor ESPRIT may agree to settle pursuant to Section
5.3.2 (NOVAVAX’s Initial Right), Section 5.3.3 (Recovery) or Section 5.3.4 (ESPRIT’s Second
Right) without the prior written consent of the other Party, which shall not be unreasonably
withheld or delayed.

     5.3.6. Payments. Notwithstanding anything to the contrary contained herein, royalties,
Milestone Payments and all other payments hereunder shall continue unabated in accordance
with the terms and conditions of this Agreements during the pendency

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-34-

 

Confidential

(including all appeals) of any action contemplated by Sections 5.3.1 (Notice) through
and including Section 5.3.6 (Payments).

     5.4. Infringement of Third Party Intellectual Property

     5.4.1. Notice and Discussion. In the event NOVAVAX or ESPRIT receive notice or
otherwise become actually aware of any facts that that ESPRIT’s making, using or selling of
a Licensed Product in the Field infringes, will infringe or is alleged by a Third Party to
infringe a Third Party patent, the Party becoming aware of same shall promptly notify the
other. NOVAVAX and ESPRIT shall thereafter attempt to agree upon a course of action, which
may include: (a) modifying of a Licensed Product or its use and manufacture so as to be
non-infringing; or (b) obtaining a license or assignment from said Third Party.

     5.4.2. Negotiations. ESPRIT and NOVAVAX shall have the right to negotiate with said
Third Party for such license or assignment to the Third Party patent. In the event that such
negotiation results in a consummated agreement, then ESPRIT shall pay any lump sum payment
and/or royalties to be paid thereunder provided NOVAVAX has had an opportunity to review and
consent to such license agreement, which shall not be unreasonably withheld or delayed. Any
of such lump sum payments or royalties to be paid by ESPRIT and its Sublicensees under such
ESPRIT negotiated agreement shall be creditable against royalties then due NOVAVAX hereunder.
In no event shall ESPRIT be entitled to credit against any royalty payments owed to the
extent that any infringement claim by a Third Party is not based solely upon a Licensed
Product described in the

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-35-

 

Confidential

above-mentioned IND (No. 63957) or where the infringement claim is not based solely on
ESPRIT’s use of the Licensed Technology.

     5.4.3. Defense. In the event that ESPRIT is charged with patent infringement by a Third
Party as a result of ESPRIT’s making, using, and/or selling a Licensed Product and it cannot
settle or has not settled such infringement pursuant to the terms above, ESPRIT shall have
the right to defend against such charge of infringement. NOVAVAX shall have the opportunity
to fully participate in such defense at its own expense. If as a result of a final
unappealable judgment in the litigation or settlement thereof with the Third Party as
described in the immediately preceding two sentences, ESPRIT is required to pay royalties or
other monies to such Third Party (“Third Party Payment”), ESPRIT may thereafter offset such
Third Party Payment (including running royalties and any and all lump sum payments) against
any royalties due but not yet paid hereunder to NOVAVAX, unless such infringement claim by a
Third Party is not based solely upon a Licensed Product described in the above-mentioned NDA
or where the infringement claim is not based solely on ESPRIT’s use of the Licensed
Technology. Any damages or other monies awarded or received in settlement of such litigation
against such adverse party shall be shared in accordance with Sections 5.3.3 (Recovery) and
5.3.4 ESPRIT’s (Second Right).

     5.4.4. Payments. Other than as expressly set forth to the contrary in Section 5.4.3
(Defense), royalties and all other payments hereunder shall continue unabated in accordance
with the terms and conditions of this Agreements during the pendency

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-36-

 

Confidential

(including all appeals) of any action contemplated by Sections 5.4.1 (Notice and
Discussion) through and including Section 5.4.4 (Payments).

ARTICLE 6. CONFIDENTIALITY AND PUBLICITY

     6.1. Confidential Information. All information disclosed by one Party to the other(s)
or developed by the parties pursuant to the terms of this Agreement (the “Confidential
Information”) shall be maintained strictly confidential and used only for the purposes of this
Agreement in accordance with this ARTICLE 6 (Confidentiality and Publicity) (“Purposes”). Each
Party may also disclose the other’s information to an Affiliate, agent or consultant, who is under
a written obligation of confidentiality and non-use at least substantially equivalent to the
obligations of this ARTICLE 6 (Confidentiality and Publicity), with the exceptions that (i) ESPRIT
may disclose such information to its Affiliates who agree to maintain such information in
confidence and to use such information only for the Purposes and (ii) the Parties shall each be
free to disclose the existence of this Agreement and the nature of the licenses granted hereunder
to its Affiliates and other prospective licensees and sub-licensees, investors or prospective
investors, lenders and other potential funding sources, or to a Third Party in connection with a
merger or acquisition or proposed merger or acquisition, subject to an obligation of
confidentiality and non-use, provided that such Party shall have used commercially reasonable
efforts to obtain a written confidentiality agreement from such Third Party contemplated by this
sentence. Each Party shall guard any confidential information of the other Party with the same
level of diligence as it normally guards any of its own most valuable internal confidential,
proprietary information. Each Party shall be responsible for the breach of any of the provisions

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-37-

 

Confidential

of this ARTICLE 6 (Confidentiality and Publicity) by a person or entity to whom such Party
discloses information contemplated hereby.

Notwithstanding the foregoing, each Party shall be relieved of the confidentiality and limited
use obligations of this Agreement if:

     (a) the information was previously known to the receiving Party as evidenced by
the prior written records of such Party without disclosure by the disclosing Party;

     (b) the information is or becomes generally available to the public through no
fault of the receiving Party;

     (c) the information is acquired in good faith in the future by the receiving
Party from a Third Party not under an obligation of confidence to the disclosing
Party with respect to such information; or

     (d) the information is independently developed by the receiving Party without
reliance on, reference to, or knowledge of, the information disclosed by the
disclosing Party.

The parties understand and agree that it shall be the receiving Party’s burden of proof to
show the applicability of any of the exceptions set forth in clauses (a), (b) (c) or (d)
above.

     6.2. Exceptions. Notwithstanding the above obligations of confidentiality and non-use
a Party may:

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-38-

 

Confidential

     (a) disclose information to a regulatory agency that is necessary to obtain
regulatory approval in a particular jurisdiction;

     (b) disclose information to a government agency if the disclosure is necessary
to protect the health and safety of the Party’s workers or the public or as required
by law; or

     (c) disclose information as and to the extent required to comply with
applicable laws and regulations, including the rules and regulations of the U.S.
Securities and Exchange Commission.

In making such disclosures as set forth in this Section 6.2 (Exceptions), the disclosing
Party shall use reasonable efforts to promptly first notify the owner of the confidential
information so as to allow the owner of the confidential information an opportunity to seek
a protective order or otherwise limit any such disclosure. In any event, the disclosing
Party shall use reasonable efforts to only disclose such information as is required to be
disclosed pursuant to the law, regulation, rule or order, and shall use its reasonable
efforts to obligate the recipient to secrecy on the same terms as set forth herein. Each
Party shall restrict the disclosure of confidential information of the other so that only
the persons that need to know it shall be informed and the disclosure be limited to only
such portions as necessary for the purposes of this Agreement.

     6.3. Use of Names. Each Party shall not state or imply, in any publication,
advertisement, sales promotional material, or other medium:

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-39-

 

Confidential

     (a) the name of the other Party or the name(s) of any employee(s) of the other
Party; or

     (b) the name of any Affiliate of the other Party or the name(s) of any
employee(s) of such Affiliate

without the prior written consent of the other Party.

     6.4. Disclosure of Agreement. Except for the filing of a copy of this Agreement with
the Securities and Exchange Commission or other securities commission of such other jurisdictions
whose laws may apply to either Party to the extent required by law and such other public
announcements as may hereafter become required by law, regulation or rule due to changes from the
facts and circumstances in existence as of the Effective Date, no Party hereunder shall disclose
this Agreement or make any public announcement or filing concerning this Agreement or the subject
matter hereof without the prior written consent of the other. In the event that pursuant to the
foregoing a Party shall file a copy of this Agreement with the Securities and Exchange Commission
or other securities commission of such other jurisdictions whose laws may apply to either Party, it
shall use reasonable efforts seek confidential treatment for all portions thereof reasonably
requested by the other Party. Any proposed announcement or filing by a Party shall be made
available to the other Party in advance of publication or filing, as the case may be, for review
and comment. If a Party decides to make an announcement or disclosure required by law or as
otherwise permitted under this Section 6.4 (Disclosure Agreement) of this Agreement, it will
provide the other Party with at least ten (10) Business Days, where possible, advance written
notice of the text of any such written announcement or

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-40-

 

Confidential

disclosure or content of any non-written disclosure or announcement, except to the extent
applicable law requiring disclosure would not permit such advance notice (such as in the case of
certain securities filings), in which case the disclosing Party will give the maximum notice
possible under the circumstances, so that the other Party will have an opportunity to comment upon
the announcement or disclosure.

     6.5. Publication. Except for permissible publications under this ARTICLE 6
(Confidentiality and Publicity), neither Party will publish any information based upon or derived
from the work performed under this Agreement without the prior review and consent of the Parties
pursuant to this Section 6.5 (Publication).

     6.6. Other Confidentiality Obligations. With respect to information disclosed on or
after the Effective Date between ESPRIT and NOVAVAX under the provisions of this Agreement, the
provisions of this Agreement shall govern and prevail. In the event of any conflict between this
Agreement and any other pending confidentiality agreement between ESPRIT and NOVAVAX, with respect
to information disclosed on or after the Effective Date, the terms of this Agreement shall govern
and prevail.

ARTICLE 7. ADVERSE EVENTS AND RECALLS

     7.1. Adverse Events. In the event that an adverse drug experience associated with the
Licensed Product arises in connection with Licensed Product, each Party shall immediately inform
the other Party by telephone communication within one (1) day of its own receipt of notice of such
adverse reaction. The informing Party will then promptly forward to the other

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-41-

 

Confidential

Party all written documentation relating to such adverse reaction, including a detailed
description of such event. ESPRIT expressly disclaims that NOVAVAX acts as an agent, designee, or
representative of ESPRIT for purposes of informing ESPRIT of such adverse reaction. NOVAVAX
expressly disclaims that ESPRIT acts as an agent, designee, or representative of NOVAVAX for
purposes of informing NOVAVAX of such adverse drug experience. If ESPRIT receives a written
communication from the FDA (or non-U.S. equivalents) relating to the Licensed Products which
relates to the development, marketing, safety or efficacy of the Licensed Products, and which would
materially affect the time for receipt of the Regulatory Approval of such Licensed Products or the
ability of the Parties to develop or market such Licensed Products, ESPRIT shall promptly provide
NOVAVAX with a copy of such communication and shall consult with NOVAVAX while taking into account
NOVAVAX’S recommendations and comments, to the extent reasonable, in responding to any
communications with the FDA or other applicable regulatory authority. If NOVAVAX receives a
written communication from the FDA or any foreign equivalent of the FDA in a country outside of the
Territory which relates to the development, marketing, safety or efficacy of the Licensed Products,
and which would affect the receipt of regulatory approval of the Registrations for the Licensed
Products in the Territory, NOVAVAX shall promptly provide ESPRIT with a copy of such communication.

     7.2. Recalls. In the event that either Party determines that an event, incident or
circumstance has occurred which may result in the need for a recall or other removal of any
Licensed Product, or any lot or lots thereof, from the market, it shall promptly advise and consult
with the other Party with respect thereto. The parties shall jointly make the final determination
to

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-42-

 

Confidential

recall or otherwise remove a Licensed Product or any lot or lots thereof from the market which
consent of NOVAVAX shall not be unreasonably withheld or delayed. ESPRIT shall be responsible for
the costs of any recall except if such recall is solely the result of any failure of NOVAVAX to
manufacture Licensed Product in accordance with written specifications agreed upon by the parties
under the Supply Agreement.

ARTICLE 8. WARRANTIES, REPRESENTATIONS AND ACKNOWLEDGEMENTS

     8.1. NOVAVAX Representations and Warranties

     8.1.1. Ownership and Authority. NOVAVAX expressly warrants and represents that (a) it
exclusively owns all of the rights, title and interest in and to the Licensed Patents
identified on Schedule 1 existing as of the date hereof, and (b) it has the full
corporate right and authority to enter into this Agreement and all necessary consents and
notices have been obtained or made as the case may be to carry out the transactions
contemplated herein. NOVAVAX further represents and warrants that as of the Effective Date
no academic institution, member of an academic institution, corporation, local, state or
federal government, or any other Third Party holds any property rights in the Licensed
Patents identified on Schedule 1, or to its knowledge other Licensed Technology, that
pertains to a Licensed Product existing as of the date hereof. Further, NOVAVAX represents
that the patent applications and patents of Schedule 1 are all the current existing
Licensed Patents reasonably relevant to the Licensed Product in the Territory having the
formulation described on Schedule 2 attached hereto (the “Formulation”).

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-43-

 

Confidential

     8.1.2. No Outstanding Encumbrances. NOVAVAX expressly warrants and represents that,
there are no outstanding encumbrances or agreements, either written, or to its knowledge if
oral or implied, on the Licensed Technology that are inconsistent with the obligations
undertaken by NOVAVAX herein, and that it has not granted and will not grant during the term
of this Agreement or any renewal hereof, any license or other privilege under the Licensed
Technology with respect to the exclusive rights granted hereunder for a Licensed Product in
the Territory in the Field which conflicts, or which could reasonably be expected to
conflict, with the terms and conditions of this Agreement.

     8.1.3. Disclosures. NOVAVAX expressly warrants and represents that, to its knowledge,
it has disclosed to ESPRIT all reasonably relevant and material regarding pre-clinical and
clinical studies and the Licensed Product in its possession or control which NOVAVAX is not
otherwise prohibited from disclosing pursuant to law, regulation, order, treaty, agreement,
contract or other obligation.

     8.1.4. Third Parties. NOVAVAX expressly warrants and represents that it is not required
to obtain the consent of any Third Party to grant the rights granted herein to ESPRIT.
NOVAVAX further expressly warrants and represents that the rights granted herein do not
conflict with any existing or pending written agreement (or to its knowledge, any existing or
pending oral or implied agreement) of NOVAVAX with a Third Party pertaining to use of the
Licensed Technology for a Licensed Product in the Territory.

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-44-

 

Confidential

     8.1.5. Infringement. NOVAVAX expressly warrants and represents that: a) it has not
been notified in writing of any claims of infringement from any Third Party with respect to
the Licensed Product as it currently exists, and, to its knowledge, no Third Party has
threatened to make any such claim; and b) that, to its knowledge, it solely owns all of the
data and results from any and all preclinical and clinical development and testing of the
Licensed Product that it conducted or authorized to have conducted prior to the Effective
Date of this Agreement, and that NOVAVAX has used reasonable efforts to disclose all of the
data from such preclinical and clinical development and testing to ESPRIT in connection with
this Agreement. NOVAVAX represents that it has not received written notice of any issued
patent owned by a Third Party which would be infringed by the making, using, and selling of a
Licensed Product having the Formula in the countries of the Territory utilizing the Licensed
Patents of NOVAVAX as currently in existence as of the date hereof in any in those countries
of the Territory.

     8.1.6. Necessary Steps. NOVAVAX represents and warrants that, to its knowledge, it has
undertaken all necessary legal and factual steps to ensure that NOVAVAX is able to license
the Licensed Technology to ESPRIT in accordance with this Agreement to ESPRIT.

     8.2. ESPRIT Representations and Warranties. ESPRIT expressly warrants and represents
that (a) it has the full corporate right and authority to enter into this Agreement and to carry
out the transactions contemplated herein; (b) it has obtained all consents necessary to enter into
and perform its obligations under this Agreement; (c) its entry into and performance of this

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-45-

 

Confidential

Agreement do not conflict with any existing or pending written agreement (or to its knowledge,
any existing or pending oral or implied agreement) of ESPRIT with a Third Party pertaining the
subject matter contained herein; and (d) it is not aware of any fact or circumstance which would
indicate that NOVAVAX is in breach of any of the representations in Sections 8.1.1 (Ownership and
Authority) through and including Section 8.1.2 (No Outstanding Encumbrances).

     8.3. DISCLAIMER. THE FOREGOING WARRANTIES OF EACH PARTY ARE IN LIEU OF ANY OTHER
WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY WARRANTIES OF MERCHANTABILITY OR
ANY WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE, VALIDITY, OR NON-INFRINGEMENT, ALL OF WHICH ARE
HEREBY SPECIFICALLY EXCLUDED AND DISCLAIMED.

     8.4. LIMITATION OF LIABILITY. EXCEPT FOR THEIR RESPECTIVE OBLIGATIONS UNDER ARTICLE
10 (INDEMNIFICATION) ARISING OUT OF THIRD PARTY CLAIMS, SUITS OR DEMANDS OR FOR ANY BREACH OF
CONFIDENTIALITY OBLIGATIONS OWED UNDER THIS AGREEMENT OR FOR ANY MISAPPROPRIATION OR INFRINGEMENT
OF ANY INTELLECTUAL PROPERTY LICENSED UNDER THIS AGREEMENT, NEITHER PARTY SHALL BE LIABLE TO THE
OTHER FOR ANY PUNITIVE, SPECIAL, INCIDENTAL, OR INDIRECT DAMAGES UNDER ANY CONTRACT, NEGLIGENCE,
STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY ARISING OUT OF OR IN CONNECTION WITH THIS
AGREEMENT OR ITS SUBJECT MATTER.

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-46-

 

Confidential

ARTICLE 9. TERM AND TERMINATION

     9.1. Term. The term of this Agreement shall commence on the Effective Date and shall
expire upon the expiration of the last-to-expire Licensed Patent or when terminated in accordance
with any of the provisions herein. Upon expiration of the term of this License Agreement, ESPRIT
shall have a fully paid-up license to make, have made, use and sell Licensed Products under the
Licensed Technology in the Field in the Territory. If this Agreement is terminated prior to the end
of the Term, all licenses granted to ESPRIT hereunder shall cease and all such licensed rights
shall revert to NOVAVAX.

     9.2. Termination for Breach. Upon any breach of, or default under, any material
provision of this Agreement by a Party, including, without limitation, nonpayment of amounts owed
hereunder by ESPRIT for any reason whatsoever except as specifically provided for in this
Agreement, the other Party may terminate this Agreement in whole or in part by giving ninety (90)
days’ written notice (the “Notice Period”) to the breaching Party; provided however, that the
breaching Party shall have seventy-five (75) days to cure any such breach prior to the commencement
of the Notice Period. Said notice shall become effective at the end of such Notice Period, unless
during said Notice Period the breaching Party shall cure such breach or default within the
applicable cure period. Notwithstanding anything to the contrary contained herein, payment
defaults will have a notice and cure period of five business (5) days.

     9.3. Additional Termination Rights of ESPRIT; ESPRIT shall have the right to terminate
this Agreement, and subject to the provisions of Section 9.4, but otherwise, without liability,
upon thirty (30) days prior notice to NOVAVAX (i) ***, that (x) *** or (y) ***. In such

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-47-

 

Confidential

event, ESPRIT shall submit sufficient supporting documentation evidencing ***, prepared by an
independent certified public accountant acceptable to NOVAVAX, and submitted to NOVAVAX for review.
If NOVAVAX agrees that the Post Phase II Development Costs are in excess of *** then Esprit may,
provide notice of termination to NOVAVAX in accordance with this Section 9.3. If the Parties do
not agree on the right of ESPRIT to terminate under this Section 9.3, then the matter shall be
reviewed by the JSC and escalated to the highest levels of review, and failing mutual resolution,
then the provisions of Article 11 regarding Dispute Resolution and Arbitration shall govern. In
the event of any termination under this Section 9.3, Section 9.4 shall apply.

     9.4. Effect of Termination by ESPRIT or NOVAVAX under Section 3.1.2, Effect of
Additional Termination Rights of ESPRIT under Section 9.3 and Effect of Termination for Breach by
ESPRIT. Except as otherwise expressly set forth herein, upon termination by NOVAVAX or ESPRIT
under Section 3.1.2 (Development Milestones), upon Termination by NOVAVAX under Section 9.2
(Termination for Breach) or upon termination by ESPRIT under Section 9.3 (Additional Termination
Rights of ESPRIT) :

     (a) all licenses granted to ESPRIT hereunder shall cease and all such licensed
rights shall revert to NOVAVAX;

     (b) ESPRIT shall, and it hereby does effective only upon termination by NOVAVAX
or ESPRIT under Section 3.1.2 (Development Milestones), upon termination by NOVAVAX
as set forth above in Section 9.2 (Termination for Breach), or upon termination by
ESPRIT as set forth above in Section 9.3 (Additional Termination Rights of ESPRIT)
grant to NOVAVAX an exclusive

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-48-

 

Confidential

(even as to ESPRIT), worldwide, irrevocable, perpetual, fully-paid up license,
under ESPRIT Improvements and ESPRIT’s interest in the Joint Improvements, with the
right to grant Sublicenses, to make and have made, import, use, sell, offer for
sale, and have sold Licensed Product in the Field.

     (c) ESPRIT shall promptly deliver to NOVAVAX all of the following documents:
(1) all confidential information and materials related to any Licensed Product
provided by NOVAVAX pursuant to this Agreement, and (2) any NDA or any other filing
with any governmental or regulatory authority worldwide in connection with any
Licensed Product, and all related data, documents, reports, files (including the
related drug master file), filings and correspondence with any governmental or
regulatory authority, adverse event reports, clinical trial results, any IND and
supporting data and information, and all other documents or information, in whatever
form, relating to the manufacture, use and sale of the Licensed Products;

     (d) if ESPRIT has applied for or obtained any regulatory approvals in any
country for any Licensed Product, then ESPRIT shall, to the extent legally
permissible, take all additional action reasonably necessary to assign all of its
right, title and interest in and transfer possession and control to NOVAVAX of such
applications or regulatory approvals; and

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-49-

 

Confidential

     (e) any regulatory filings for any Licensed Product which have been submitted
in ESPRIT’s name, subject to FDA approval, will be transferred to NOVAVAX’s name.

     9.5. Effect of Termination for Breach by NOVAVAX. Except as otherwise expressly set
forth herein, upon termination by ESPRIT under Section 9.2 (Termination for Breach) ESPRIT shall be
free of any obligation to make any unaccrued payments to NOVAVAX relating to the terminated license
pursuant to ARTICLE 4 (Payments).

     9.6. Termination for Bankruptcy. NOVAVAX or ESPRIT may terminate this Agreement
should the other Party commit an act of bankruptcy, be declared bankrupt, voluntarily file or have
filed against it a petition for bankruptcy or reorganization unless such petition is dismissed
within sixty (60) days of filing, enter into a procedure of winding up to dissolution or should a
trustee or receiver be appointed for its business assets or operations. All rights and licenses
granted under or pursuant to this Agreement are, and shall otherwise be deemed to be, for the
purposes of Section 365(n) of Title 11, U.S. Code (“Bankruptcy Code”) license rights to
“intellectual property” as defined under Section 101 (35A) of the Bankruptcy Code. The parties
agree that each Party, as a licensee of such right, under this Agreement, shall retain and may
fully exercise all of its rights and elections under the Bankruptcy Code.

     9.7. Certain Effects of Termination; Payments and Dispute Resolution. In the event of
termination of this Agreement for any reason, all licenses granted to ESPRIT hereunder shall cease
and all licensed rights shall revert to NOVAVAX, and ESPRIT shall not be relieved of the duty and
obligation to pay in full, payments due, accrued, and unpaid at the effective date

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-50-

 

Confidential

of such termination, nor shall any such termination relieve either Party of any obligation
arising hereunder prior to such termination. Notwithstanding the foregoing, from the date either
Party notifies the other Party that it wishes to commence a proceeding in accordance with the
dispute resolution procedures set forth in ARTICLE 11 (Arbitration) until the date such proceeding
has been concluded, the running of the time period referred to in this paragraph for curing a
breach shall be suspended with respect to the subject matter of the dispute, claim or controversy.

     9.8. Sell Off Right. Upon termination of any license granted herein, in part or in
whole as to any Licensed Product, ESPRIT shall have the right to sell off any of such Licensed
Product in its inventory for a period of 180 days following the effective date of such termination
provided that ESPRIT pays to NOVAVAX any royalties otherwise calculated in accordance with this
Agreement.

     9.9. Survival of Provisions Upon Termination. (a) In the event of termination of this
Agreement by NOVAVAX under Section 9.2 (Termination for Breach), the provisions of Section 2.3
(License Under ESPRIT Technology) and the provisions listed in subsection (b) below shall survive
the termination of this Agreement to the extent provided for herein, and (b) the following
provisions shall survive the termination or expiration of this Agreement to the extent of any
claims thereunder arising out of facts or circumstances arising or existing prior to the date of
such termination of expiration : ARTICLE 6 (Confidentiality and Publicity), ARTICLE 10
(Indemnification), ARTICLE 11 (Arbitration) and ARTICLE 12 (Miscellaneous), and Sections 2.3
(License under ESPRIT Technology), 3.2.3 (Access to Data and Regulatory Approvals and
Registrations), 4.6 (Audits), 8.3 (Disclaimer), 8.4 (Limitation of Liability), 9.3

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-51-

 

Confidential

(Effect of Termination for Breach by ESPRIT), 9.5 (Effect of Termination by ESPRIT or NOVAVAX
under Section 3.1.2, Effect of Termination by ESPRIT under Section 9.3 or Termination for Breach
by ESPRIT.), 9.5 (Effect of Termination for Breach by NOVAVAX), 9.7 (Certain Effects of
Termination; Payments and Dispute Resolution), 9.8 (Sell Off Right) and 9.9 (Survival of Provisions
Upon Termination).

ARTICLE 10. INDEMNIFICATION

     10.1. Generally. NOVAVAX and ESPRIT will each defend as the case maybe (each an
"Indemnifying Party”), at its own expense, indemnify and hold harmless the other Party and its
Affiliates (each an “Indemnified Party”) from and against any and all damages, liabilities, losses,
costs, and expenses, including attorneys fees (collectively, “Liabilities"), arising out of any
claim, suit or proceeding brought against the Indemnified Party (each a “Claim”) to the extent such
Claim is based upon a claim arising out of or relating to (i) any breach or violation of, or
failure to perform, any covenant or agreement made by such Indemnifying Party in this Agreement,
unless waived in writing by the Indemnified Party; (ii) any breach of the representations or
warranties made by such Indemnifying Party in this Agreement; or (iii) the negligence or willful
misconduct of the indemnifying Party, except, under clause (ii), to the extent arising out of the
breach, violation, failure, negligence or willful misconduct of the Indemnified Party.

     10.2. Product Liability. Except as otherwise provided herein, ESPRIT (as the
Indemnifying Party) will defend, at its own expense, indemnify and hold harmless NOVAVAX and its
Affiliates (as the Indemnified Parties) from and against all Liabilities arising out of any

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-52-

 

Confidential

Claim to the extent such Claim is based upon a claim arising out of or relating to any
personal injury or death of any Person as a result of the use of any Licensed Product sold by
ESPRIT, its Affiliates or Sublicensees, except to the extent such Claim is due to the manufacture
of Licensed Products supplied by NOVAVAX other than in accordance with specifications as provided
in the Supply Agreement or the negligent, grossly negligent, or intentional act or omission of
NOVAVAX and its Affiliates. Similarly, NOVAVAX (as the Indemnifying Party) will defend, at its own
expense, indemnify and hold harmless the ESPRIT and its Affiliates (as Indemnified Parties) from
and against any and all Liabilities arising out of any Claim brought against ESPRIT or any such
Affiliate to the extent such Claim is based upon a claim arises out of a Third Party claim or suit
or demand based on bodily injury or property damage resulting from the manufacture of Licensed
Product supplied by NOVAVAX other than in accordance with specifications as provided in the Supply
Agreement, unless such claim is due to the negligent, grossly negligent or intentional act or
omission of ESPRIT.

     10.3.
Claims. If any Claim is made by a Third Party (a
“Third Party Claim”) against
an Indemnified Party that, if sustained, would give rise to Liability to an Indemnifying Party
under this Agreement, the Indemnified Party shall promptly cause notice of the claim to be
delivered to the Indemnifying Party along with all of the facts, information or materials relating
to such claim of which the Indemnified Party is aware; provided, however, that
failure to give such notification shall not affect the indemnification provided for hereunder
except to the extent that the Indemnifying Party shall have been actually prejudiced as a result of
such failure. The Indemnified Party shall deliver to the Indemnifying Party, within five days
after the Indemnified Party’s receipt thereof, copies of all notices and documents (including court
papers) received by

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-53-

 

Confidential

the Indemnified Party relating to such Third Party Claim. If a Third Party Claim is made
against an Indemnified Party, the Indemnifying Party will be entitled to participate in the defense
thereof and, if it so chooses, to assume the defense thereof with counsel selected by the
Indemnifying Party and reasonably satisfactory to the Indemnified Party. Should the Indemnifying
Party so elect to assume the defense of a Third Party Claim, the Indemnifying Party will not be
liable to the Indemnified Party for legal expenses subsequently incurred by the Indemnified Party
in connection with the defense thereof, unless the Third Party Claim involves potential conflicts
of interest or substantially different defenses for the Indemnified Party and the Indemnifying
Party. If the Indemnifying Party assumes such defense, the Indemnified Party shall have the right
to participate in the defense thereof and to employ counsel, at its own expense (except as provided
in the immediately preceding sentence), separate from the counsel employed by the Indemnifying
Party, it being understood that the Indemnifying Party shall control such defense. The
Indemnifying Party shall be liable for the reasonable fees and expenses of counsel employed by the
Indemnified Party for any period during which the Indemnifying Party has not assumed the defense of
any Third Party Claim that, if sustained, would give rise to a Liability of the Indemnifying Party
under this Agreement. The parties shall cooperate in the defense or prosecution of any Third Party
Claim. Such cooperation shall include the retention and (upon the Indemnifying Party’s request)
the provision to the Indemnifying Party of records and information that are reasonably relevant to
such Third Party Claim, and reasonable efforts to make employees available on a mutually convenient
basis to provide additional information and explanation of any material provided hereunder.
Whether or not the Indemnifying Party shall have assumed the defense of a Third Party Claim, the
Indemnified Party shall not admit any Liability with respect

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-54-

 

Confidential

to, or settle or compromise a Third Party Claim without the Indemnifying Party’s prior written
consent (which consent shall not be unreasonably withheld). The Indemnifying Party may pay, settle
or compromise a Third Party Claim (i) with the written consent of the Indemnified Party, not to be
unreasonably withheld or delayed or (ii) without the written consent of the Indemnified Party, so
long as such settlement includes (A) an unconditional release of the Indemnified Party from all
Liability in respect of such Third Party Claim and (B) does not subject the Indemnified Party to
any injunctive relief or other equitable remedy. In the event an Indemnified Party has a claim
against an Indemnifying Party that does not involve a Third Party Claim, the Indemnified Party
shall promptly cause notice of such claim to be delivered to the Indemnifying Party. If the
Indemnifying Party disputes such claim, the Indemnifying Party and the Indemnified Party shall
attempt in good faith for a period of 10 days to settle any such dispute. If the parties are
unable to resolve such dispute, the Indemnified Party may pursue any and all courses of action
available against the Indemnifying Party.

     10.4. Limits to Obligations. An Indemnifying Party’s (including Sublicensees)
obligations under this ARTICLE 10 (Indemnification) shall not extend to any Claims for Liability
arising from the Indemnified Party’s failure to comply with the terms and conditions of this
Agreement or arising from the negligence, gross negligence, intentional wrongful act or omission of
the Indemnified Party, its agents or employees.

ARTICLE 11. ARBITRATION

     Any controversy or claim arising out of or relating to this Agreement shall be resolved by
arbitration before a panel of three arbitrators in accordance with the Commercial Arbitration

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-55-

 

Confidential

Rules of the American Arbitration Association (“AAA”) then pertaining (available at www.adr.org),
except where those rules conflict with this provision, in which case this provision controls. Any
court with jurisdiction shall enforce this clause and enter judgment on any award. The arbitrators
shall be selected within twenty Business Days from filing of a demand for arbitration from the
AAA’s National Roster of Arbitrators pursuant to agreement or through selection procedures
administered by the AAA. Within 45 days of filing of a demand for arbitration, the parties shall
reach agreement upon and thereafter follow procedures, including limits on discovery, assuring that
the arbitration will be concluded and the award rendered within no more than eight months from
selection of the arbitrators or, failing agreement, procedures meeting such time limits will be
designed by the AAA and adhered to by the parties. The arbitration shall be held in New York, New
York, Borough of Manhattan and the arbitrators shall apply the substantive law of New York, except
that the interpretation and enforcement of this arbitration provision shall be governed by the
Federal Arbitration Act. Prior to commencement of arbitration, emergency relief is available from
any court to avoid irreparable harm. THE ARBITRATOR SHALL NOT AWARD EITHER PARTY PUNITIVE,
EXEMPLARY, MULTIPLIED OR CONSEQUENTIAL DAMAGES, OR ATTORNEYS FEES OR COSTS, OTHER THAN IN
CONNECTION WITH A BREACH BY EITHER PARTY OF ITS CONFIDENTIALITY OBLIGATIONS UNDER THIS AGREEMENT OR
AS DAMAGES FOR ANY MISAPPROPRIATION OF INFRINGEMENT OF INTELLECTUAL PROPERTY LICENSED UNDER THIS
AGREEMENT. Prior to commencement of arbitration, the parties must attempt to mediate their dispute
using a professional mediator from AAA, the CPR Institute for Dispute Resolution, or like
organization selected by agreement or, absent agreement, through

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-56-

 

Confidential

selection procedures administered by the AAA. Within a period of forty-five (45) days after the
request for mediation, the parties agree to convene with the mediator, with business
representatives present, for at least one session to attempt to resolve the matter. In no event
will mediation delay commencement of the arbitration for more than forty-five (45) days absent
agreement of the parties or interfere with the availability of emergency relief.

ARTICLE 12. MISCELLANEOUS

     12.1. Force Majeure. Any delays in or failures of performance by a Party under this
Agreement shall not be considered a breach of this Agreement if and to the extent caused by acts of
God; acts, changes in the regulations or laws of any government; strikes or other concerted acts of
workers (other than strikes or acts of such Party’s own workers); fires; floods; explosions; riots;
wars; rebellions; and sabotage (a “Force Majeure Event”); and any time for performance hereunder
shall be extended by the actual time of delay caused by such occurrence. In the event that a
Party’s performance of payment obligations is suspended for more than one hundred and twenty (120)
days because of a Force Majeure Event, the other Party has the right to terminate this Agreement
upon written notice to the non-performing Party.

     12.2. Assignment. This Agreement, or any of the rights and obligations created
herein, including but not limited to the licenses granted under ARTICLE 2 (Grant of Rights), shall
not be assigned or transferred, in whole or in part, by either Party hereto without the prior
written consent of the other Party which will not be unreasonably withheld or delayed; provided,
however, that either Party may, without such consent, assign the Agreement and its rights and
obligations hereunder (A) to a wholly owned operating Affiliate of such Party or (B) in

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-57-

 

Confidential

connection with the transfer or sale of all or substantially all of its assets to a Third
Party so long as: (i) each Party will provide the other Party with at least ten (10) days prior
written notice thereof; and (ii) in the event of such a transfer by NOVAVAX, any permitted
assignee shall assume all obligations of its assignor under the Agreement in a writing delivered to
the other Party. Any attempted assignment or transfer of such rights or obligations without such
consent, except as provided herein, shall be void. This Agreement shall binding upon any purchaser
of all or substantially all of the assets of the either Party, as the case may be. This Section
12.2 (Assignment) shall not be deemed to otherwise prohibit or otherwise apply to a change in
control of NOVAVAX (whether by merger of sale of capital stock or otherwise) at the shareholder or
Board of Director levels or otherwise.

     12.3. No Waiver. The waiver by a Party, whether express or implied, of any provisions
of this Agreement, or of any breach or default of a Party, shall not be construed to be a
continuing waiver of such provision, or of any succeeding breach or default or of a waiver of any
other provisions of this Agreement.

     12.4. Choice of Law. All matters affecting the interpretation, validity, and
performance of this Agreement shall be governed by the laws of the State of New York, U.S.A.,
without regard to its choice or conflict of law principles.

     12.5. Severability. Any provision hereof which is prohibited or unenforceable in any
jurisdiction shall, as to such jurisdiction, be ineffective only to the extent of such prohibition
or unenforceability without invalidating the remaining provisions hereof or affecting the validity
or enforceability of such provision in any other jurisdiction. The parties shall replace such

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-58-

 

Confidential

ineffective provision for such jurisdiction with a valid and enforceable provision which most
closely approaches the NOVAVAX, intent, and purpose of this Agreement, and in particular, the
provision to be replaced.

     12.6. Independent Contractors. ESPRIT and NOVAVAX are independent contractors and
shall not be deemed to be partners, joint venturers or each other’s agents, and neither shall have
the right to act on behalf of the other except as expressly provided hereunder or otherwise
expressly agreed to in writing.

     12.7. Entire Agreement. It is the mutual desire and intent of the parties to provide
certainty as to their future rights and remedies against each other by defining the extent of their
mutual undertakings as provided herein. The parties have in this Agreement incorporated all
representations, warranties, covenants, commitments and understandings on which they have relied in
entering into this Agreement and, except as provided for herein, neither Party has made any
covenant or other commitment to the other concerning its future action. Accordingly, this
Agreement (together with the schedules attached hereto (i) constitute the entire agreement and
understanding between the parties with respect to the matters contained herein, and there are no
promises, representations, conditions, provisions or terms related thereto other than those set
forth in this Agreement, and (ii) supersede all previous understandings, agreements and
representations between the parties, written or oral relating to the subject matter hereof. The
parties hereto may from time to time during the continuance of this Agreement modify, vary or alter
any of the provisions of this Agreement, but only by written agreement of all parties hereto.

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-59-

 

Confidential

     12.8. Notice to Parties. All communications, reports, payments and notices required
by this Agreement shall be addressed to the Partied(s) at their respective address(s) set forth
below or to such other address as requested by a Party by notice in writing to the other parties.

	 	 	 	 	 
	 

	 	If to NOVAVAX:
	 	Attention: Chief Executive Officer
	 

	 	 	 	NOVAVAX, Inc.
	 

	 	 	 	508 Lapp Road
	 

	 	 	 	Malvern, PA 19355
	 
	 	 	 	 
	 

	 	With a copy to:
	 	Attention: Legal Department
	 

	 	 	 	NOVAVAX, Inc.
	 

	 	 	 	508 Lapp Road
	 

	 	 	 	Malvern, PA 19355
	 
	 	 	 	 
	 

	 	If to ESPRIT:
	 	Attention: Chief Executive Officer
	 

	 	 	 	ESPRIT Pharma, Inc.
	 

	 	 	 	Two Tower Blvd.
	 

	 	 	 	East Brunswick, NJ 08816
	 
	 	 	 	 
	 

	 	With a copy to:
	 	Steven M. Bosacki, General Counsel
	 

	 	 	 	ESPRIT Pharma, Inc.
	 

	 	 	 	Two Tower Blvd.
	 

	 	 	 	East Brunswick, NJ 08816

     All such notices, reports, payments and communications shall be made by First Class
mail; postage prepaid, and shall be considered made as of the date of deposit with the
United States Post Office.

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-60-

 

Confidential

     12.9. Modification. This Agreement may not be amended or modified unless in writing
executed by both parties hereto. Except as otherwise expressly set forth herein, neither party
will have any rights of setoff or to withhold the performance of any obligation (including with
respect to any payment otherwise required to be made) hereunder.

     12.10. Terms. Unless otherwise expressly provided for herein (i) financial and
accounting terms will have the meaning ascribed to such terms in accordance with GAAP, (ii) the
word, “including”, will mean “including but not limited to” and the word “day” will mean “calendar
day”, (iii) references to the singular will include the plural and vice versa, (iv) the use of any
pronoun will include the neuter and both genders, and (v) references to Sections, Articles,
Schedules and Exhibits will be references to Sections, Articles, Schedules and Exhibits to this
Agreement and the word, “herein” and words of similar import will be construed to refer to this
Agreement, (vi) the word “knowledge” will mean actual knowledge after reasonably diligent inquiry
of executive officers of the relevant entity, and (vii) headings and titles of Sections and
Articles herein will be construed to be descriptive only and without any substantive or
interpretive effect.

     12.11. Consent to Grant of Security Interest

     NOVAVAX does hereby consent to the granting of a security interest in this Agreement and the
Supply Agreement dated as of the date hereof, in favor of any secured lender designated by ESPRIT.
Moreover NOVAVAX agrees to execute whatever other documentation may be reasonably required in
connection with such consent.

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-61-

 

Confidential

ARTICLE 13. TAXES

     13.1. ESPRIT Payments. ESPRIT will make all payments to NOVAVAX under this Agreement
without deduction or withholding for taxes except to the extent that any such deduction or
withholding is required by law in effect at the time of payment.

     13.2. Proof of Payment. Any tax required to be withheld on amounts payable under this
Agreement will promptly be paid by ESPRIT on behalf of NOVAVAX to the appropriate governmental
authority, and ESPRIT will furnish NOVAVAX with proof of payment of such tax.

     13.3. Cooperation. ESPRIT and NOVAVAX will cooperate with respect to all
documentation required by any taxing authority or reasonably requested by ESPRIT to secure a
reduction in the rate of applicable withholding taxes.

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-62-

 

Confidential

	 	 	 	 	 	 	 	 	 	 	 
	NOVAVAX, INC.	 	 	 	ESPRIT PHARMA, INC.	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	 	 	 	 	By:	 	 	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	Name: Rahul Singhvi	 	 	 	Name: Greg Stokes	 	 
	Title: President and Chief Executive Officer	 	 	 	Title: President & Chief Operating Officer	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Date:

	 	 	 	 	 	Date:	 	 	 	 
	 

	 	 

	 	 	 	 	 	 

	 	 

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-63-

 

Confidential

LICENSE AND DEVELOPMENT AGREEMENT

Schedule 1 — Patents and Patent Applications

	 	 	 	 	 	 	 	 	 	 	 
	Country	 	Status	 	Application No.	 	Patent No.	 	Issue Date	 	Expiration
	United States

	 	Granted
	 	08/380942
	 	5629021
	 	05/13/1997
	 	01/31/2015
	Mexico

	 	Granted
	 	975663
	 	198438
	 	09/04/2000
	 	01/29/2016
	Canada

	 	Granted
	 	2211262
	 	2211262
	 	08/30/2005
	 	01/29/2016

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-64-

 

Confidential

LICENSE AND DEVELOPMENT AGREEMENT

Schedule 2 — Formulation For Existing Licensed Product

Formulation (to be added)

	 	 	 
	Ingredient Description	 	Percent w/w
	Testosterone
USP/EP

	 	***
	Soybean Oil USP

	 	***
	Polysorbate 80 NF

	 	***
	190 Proof Ethyl Alcohol USP

	 	***
	Purified Water USP

	 	***

Novavax Esprit License and Development Agreement —

					
	 	 	 	 	 
	Execution Copy
	 	 
	 	 

-65-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}]]